Pathophysiology of Type 2 Diabetes Mellitus Authors: Unai Galicia-Garcia, Asier Benito-Vicente, Shifa Jebari, Asier Larrea-Sebal, Haziq Siddiqi, Kepa B. Uribe, Helena Ostolaza, César Martín Published: 2020, International journal of molecular sciences DOI: 10.3390/ijms21176275 ABSTRACT Type 2 Diabetes Mellitus (T2DM), one of the most common metabolic disorders, is caused by a combination of two primary factors: defective insulin secretion by pancreatic β-cells and the inability of insulin-sensitive tissues to respond appropriately to insulin. Because insulin release and activity are essential processes for glucose homeostasis, the molecular mechanisms involved in the synthesis and release of insulin, as well as in its detection are tightly regulated. Defects in any of the mechanisms involved in these processes can lead to a metabolic imbalance responsible for the development of the disease. This review analyzes the key aspects of T2DM, as well as the molecular mechanisms and pathways implicated in insulin metabolism leading to T2DM and insulin resistance. For that purpose, we summarize the data gathered up until now, focusing especially on insulin synthesis, insulin release, insulin sensing and on the downstream effects on individual insulin-sensitive organs. The review also covers the pathological conditions perpetuating T2DM such as nutritional factors, physical activity, gut dysbiosis and metabolic memory. Additionally, because T2DM is associated with accelerated atherosclerosis development, we review here some of the molecular mechanisms that link T2DM and insulin resistance (IR) as well as cardiovascular risk as one of the most important complications in T2DM. 1. INTRODUCTION Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide and its development is primarily caused by a combination of two main factors: defective insulin secretion by pancreatic β-cells and the inability of insulin-sensitive tissues to respond to insulin [ 1 ]. Insulin release and action have to precisely meet the metabolic demand; hence, the molecular mechanisms involved in the synthesis and release of insulin, as well as the insulin response in tissues must be tightly regulated. Therefore, defects in any of the mechanisms involved can lead to a metabolic imbalance that leads to the pathogenesis of T2DM. This review analyses the key aspects of T2DM, as well as the molecular mechanisms and pathways implicated in insulin metabolism and associations between T2DM and cardiovascular pathophysiology. In this review, we describe the global trends of T2DM, the roles of major risk factors, in particular, obesity, lifestyle factors, genetic predispositions, gut dysbiosis, epigenetics and mitochondrial deregulation. We highlight physiological and molecular mechanisms leading to T2DM and its complications. 2. TYPE 2 DIABETES MELLITUS: BACKGROUND AND EPIDEMIOLOGY According to the World Health Organization (WHO) diabetes mellitus is a chronic, metabolic disease characterized by elevated levels of blood glucose, which leads over time to damage to the heart, vasculature, eyes, kidneys and nerves. Over 90% of diabetes mellitus cases are T2DM, a condition marked by deficient insulin secretion by pancreatic islet β-cells, tissue insulin resistance (IR) and an inadequate compensatory insulin secretory response [ 2 , 3 ]. Progression of the disease makes insulin secretion unable to maintain glucose homeostasis, producing hyperglycaemia. Patients with T2DM are mostly characterized by being obese or having a higher body fat percentage, distributed predominantly in the abdominal region. In this condition, adipose tissue promotes IR through various inflammatory mechanisms, including increased free fatty acid (FFA) release and adipokine deregulation. The main drivers of the T2DM epidemic are the global rise in obesity, sedentary lifestyles, high caloric diets and population aging, which have quadrupled the incidence and prevalence of T2DM [ 4 , 5 ]. The organs involved in T2DM development include the pancreas (β-cells and α-cells), liver, skeletal muscle, kidneys, brain, small intestine, and adipose tissue [ 6 ]. Evolving data suggest a role for adipokine dysregulation, inflammation, and abnormalities in gut microbiota, immune dysregulation, and inflammation have emerged as important pathophysiological factors [ 7 ]. Epidemiological data show alarming values that predict a worrisome projected future for T2DM. According to the International Diabetes Federation (IDF), in 2019, diabetes caused 4.2 million deaths; and 463 million adults aged between 20 and 79 years old were living with diabetes, a number that will likely rise up to 700 million by 2045. Diabetes was the underlying cause of at least 720 billion USD in health expenditure in 2019. Additionally, the true disease burden of T2DM is likely an underrepresentation as 1 in 3 diabetic people were underdiagnosed, equivalent to 232 million people. The greatest number of people suffering from diabetes are aged between 40 and 59 years old. Incidence and prevalence of T2DM vary according to geographical region, with more than 80% of patients living in low-to-middle-income countries, which poses additional challenges in effective treatment. Patients with T2DM have a 15% increased risk of all-cause mortality compared with people without diabetes with cardiovascular disease (CVD) as the greatest cause of morbidity and mortality associated with T2DM [ 8 ]. The association of diabetes with increased risk of coronary heart disease (hazard ratio [HR] 2.00; 95% CI 1.83–2.19), ischaemic stroke (HR 2.27; 1.95–2.65), and other vascular disease-related deaths (HR 1.73; 1.51–1.98) has been shown in a meta-analysis [ 9 ]. Epidemiology of T2DM is affected both by genetics and the environment. Genetic factors exert their effect following exposure to an environment characterized by sedentary behavior and high-calorie intake. Common glycaemic genetic variants for T2DM have been identified by genome-wide association studies, but these only account for 10% of total trait variance, suggesting that rare variants are important [ 10 ]. People of different ethnic origins may have different specific phenotypes that increase predisposition to clusters of CVD risk factors, including hypertension, insulin resistance, and dyslipidemia [ 11 ]. 3. RISK FACTORS AND PATHOPHYSIOLOGY T2DM risk factors include a complex combination of genetic, metabolic and environmental factors that interact with one another contributing to its prevalence. Although individual predisposition to T2DM due to non-modifiable risk factors (ethnicity and family history/genetic predisposition) has a strong genetic basis, evidence from epidemiological studies suggests that many cases of T2DM can be prevented by improving the main modifiable risk factors (obesity, low physical activity and an unhealthy diet) [ 12 , 13 ]. Globally, the incidence and prevalence of T2DM are found to vary widely depending on ethnicity and geographical region with Japanese, Hispanics and Native Americans having the highest risks [ 14 , 15 , 16 ]. It has been shown higher incidence rates in Asians compared with a White American population [ 17 , 18 ], and white population in the UK, [ 19 ], where the highest risk is among the black population [ 20 ]. Whilst no clear reasons have been found, contributing factors such as modern lifestyle factors (which promote obesity), socioeconomic and direct genetic propensity or gene environmental interactions have been postulated. Genetic predisposition plays an important part in the risk of developing T2DM. Over the past decade, several T2DM genome-wide association studies have shown the complex polygenic nature of T2DM in which most of these loci increase T2DM risk through primary effects on insulin secretion, and a minority act through reducing insulin action [ 21 , 22 ]. Dimas et al. grouped these variants on the basis of their potential intermediate mechanisms in T2DM pathophysiology, with four variants fitting a clear IR pattern; two reducing insulin secretion with fasting hyperglycemia; nine lowering insulin secretion with normal fasting glycemia; and one altering insulin processing [ 23 ]. According to these data, the genetic architecture of T2DM is highly polygenic, and additional association studies are needed to identify most T2DM loci [ 24 ]. Interactions between susceptibility loci and environmental factors could underlie the missing heritability of T2DM thus the impact of a given genetic variant can be modulated by the environmental factors (and vice versa) as evidenced by both observational studies and clinical trials [ 25 ]. 3.2. OBESITY, LOW PHYSICAL ACTIVITY AND UNHEALTHY DIET Obesity (body-mass index [BMI]≥30 kg/m 2 ) is the strongest risk factor for T2DM [ 26 , 27 ] and is associated with metabolic abnormalities resulting in IR [ 28 ]. There exist an inverse linear relationship between BMI and the age at diagnosis of T2DM [ 29 ]. The exact mechanisms by which obesity induces T2DM and IR remain to be elucidated; however, numerous factors have shown a significant role in the development of this pathological process, which involves both cell-autonomous mechanisms and inter-organ communications. A sedentary lifestyle is another risk factor for T2DM as shown by the Women’s Health Study and in the Kuipio Ischemic Heart Disease Risk Factor Study, which showed a reduction of 34% and 56% reduction of developing T2DM in participants walking 2–3 h a week or at least 40 min a week, respectively [ 30 , 31 ]. There are three primary benefits of physical activity on the delay of T2DM onset. First, the contraction of skeletal muscle cells induces an increase in blood flow into the muscle, enhancing glucose uptake from plasma [ 32 ]. Second, physical activity reduces the notorious intra-abdominal fat, which is a known risk factor that promotes IR [ 33 ]. Finally, moderate-intensity exercise has been shown to improve glucose uptake by 40% [ 34 ]. Physical activity improves glucose uptake and insulin sensitivity but it can also improve or even reverse inflammation and oxidative stress, which are T2DM predisposing factors [ 32 ]. 3.3. PATHOPHYSIOLOGY Regarding the pathophysiology of the disease, a malfunctioning of the feedback loops between insulin action and insulin secretion results in abnormally high glucose levels in blood [ 2 ]. In the case of β-cell dysfunction, insulin secretion is reduced, limiting the body’s capacity to maintain physiological glucose levels. On the other hand, IR contributes to increased glucose production in the liver and decreased glucose uptake both in the muscle, liver and adipose tissue. Even if both processes take place early in the pathogenesis and contribute to the development of the disease, β-cell dysfunction is usually more severe than IR. However, when both β-cell dysfunction and IR are present, hyperglycaemia is amplified leading to the progression of T2DM [ 35 , 36 ]. 4. MECHANISMS LEADING TO T2DM AND PATHOPHYSIOLOGY To safeguard proper β-cell function, cellular integrity must be ensured and the mechanisms and pathways implicated in the physiology of β-cell must be tightly regulated [ 35 ]. β-cells are responsible for insulin production, which is synthesized as pre-proinsulin. In the maturation process, pre-proinsulin undergoes a conformational modification carried out with the help of several proteins in the endoplasmic reticulum (ER) to yield proinsulin [ 37 ]. Afterwards, proinsulin is translocated from the ER to the Golgi apparatus (GA), entering into immature secretory vesicles and being cleaved into C-peptide and insulin [ 38 , 39 ]. Once matured, insulin is stored in granules until insulin release is triggered. Insulin release is primarily triggered by a response to high glucose concentrations. It is worth noting that some other factors can also induce insulin release such as amino acids, fatty acids and hormones [ 40 ]. When circulating glucose levels increase, β-cells take in glucose mainly through the glucose transporter 2 (GLUT2), a solute carrier protein that also works as a glucose sensor for β-cells. Once glucose enters, glucose catabolism is activated, increasing the intracellular ATP/ADP ratio, which induces the closing of ATP-dependant potassium channels in the plasma membrane. This leads to membrane depolarization and opening of the voltage dependant Ca 2+ channels, enabling Ca 2+ to enter the cell. The rise in the intracellular Ca 2+ concentration triggers the priming and fusion of the secretory insulin-containing granules to the plasma membrane, resulting in insulin exocytosis [ 38 , 40 , 41 , 42 ] ( Figure 1 A). Additionally, Ca 2+ signals can be amplified by the RY receptors (RYR) and may play important roles in stimulus- insulin secretion coupling by virtue of their strategic locations within the cell and their ability to mediate Ca 2+ induced Ca 2+ release (CICR). RYR amplifies Ca 2+ signals when the channel is sensitized by messenger molecules generated from the nutrient metabolism or ligand-binding and are involved in the amplification of insulin secretion [ 43 ] ( Figure 1 A). Nevertheless, other cell signals can also assist or enhance insulin release from β-cells. Among them, cAMP might be the most important messenger potentiating insulin release. Accumulated evidence suggests that cAMP induces insulin-containing secretory vesicle mobilization by depleting intracellular Ca 2+ reservoirs, thereby increasing intracellular Ca 2+ concentrations [ 44 ]. There is also compelling evidence that extracellular ATP is another important regulator of β-cell function. It is well-documented that β-cells release ATP through exocytosis of insulin granules upon glucose stimulation. Purinergic signaling via P2Y and P2X purinergic receptors stimulates Ca 2+ mobilization and regulates insulin exocytosis also independently of glucose. P2Y purinoreceptors have been reported to be coupled to G-proteins [ 45 , 46 ] whereas P2X-type receptors are ATP-activated ligand-gated ion channels non-selective for cations [ 47 ]. In the case of P2Y receptors, it has been proposed that insulin release could be mediated by intracellular Ca 2+ mobilization in response to inositol-1,4,5-trisphosphate (IP3) formation that triggers the release of Ca 2+ from ER stores, which amplifies the exocytosis-triggering Ca 2+ signal [ 48 , 49 ] ( Figure 1 A). 4.1.2. MECHANISMS LEADING TO Β-CELL DYSFUNCTION β-cell dysfunction has been traditionally associated with β-cell death [ 50 ]. However, recent evidence suggests that the dysfunction of β-cells in T2DM might be due to a more complex network of interactions between the environment and different molecular pathways implicated in cell biology [ 51 ]. In an excessive nutritional state, similar to that found in obesity, hyperglycemia and hyperlipidemia are often present, favoring IR and chronic inflammation. Under these circumstances, β-cells, due to differences in their genetic susceptibility, are subject to toxic pressures including inflammation, inflammatory stress, ER stress, metabolic/oxidative stress, amyloid stress, with the potential of ultimately leading to a loss of islet integrity [ 50 ]. An excess of FFAs and hyperglycemia lead to β-cell dysfunction by inducing ER stress through the activation of the apoptotic unfolded protein response (UPR) pathways [ 52 ]. In fact, lipotoxicity, glucotoxicity and glucolipotoxicity occurring in obesity, induce metabolic and oxidative stress that leads to β-cell damage [ 51 ]. Stress derived from high levels of saturated FFAs can activate the UPR pathway by several mechanisms including inhibition of the sarco/endoplasmic reticulum Ca 2+ ATPase (SERCA) responsible for ER Ca 2+ mobilization; activation of IP3 receptors or direct impairment of ER homeostasis. In addition, sustained high glucose levels increase proinsulin biosynthesis and islet amyloid polypeptides (IAAP) in β-cells, leading to the accumulation of misfolded insulin and IAAP and increasing the production of oxidative protein folding-mediated reactive oxygen species (ROS) [ 52 ]. These effects alter physiological ER Ca 2+ mobilization and favor proapoptotic signals, proinsulin mRNA degradation and induce interleukin (IL)-1 β release that recruits macrophages and enhances local islet inflammation [ 51 ] ( Figure 1 B). As previously mentioned, insulin secretion has to be finely regulated to precisely meet metabolic demand. For that reason, proper islet integrity must be conserved in order to allow β-cells to respond to metabolic needs. Under pathogenic conditions, the mechanism described above can ultimately lead to disruption of islet integrity/organization, impairing optimal cell-to-cell communication within pancreatic islets, contributing to poor regulation of insulin and glucagon release and ultimately exacerbating the hyperglycemia. Defects in the synthesis of any insulin precursors, or insulin itself, as well as disruption of the secretion mechanism, can lead to insulin secretory dysfunction, the primary driver of β-cell failure, and a foundation of T2DM. For instance, reduced expression in the GLUT2 glucose transporter would affect the downstream signaling pathway [ 53 ], while failure in the folding of proinsulin is another finding commonly linked to deficient insulin production and diabetes [ 54 ]. 4.1.3. PATHOLOGICAL CONDITIONS PERPETUATING T2DM High-caloric Western diet contains large amounts of fats and carbohydrates that elevate blood glucose and circulating very-low-density lipoproteins (VLDLs), chylomicrons (CMs) and their remnants (CMRs) that are rich in triglycerides (TG). This induces a spike in reactive oxygen species (ROS) concentrations, which in turn leads to an abnormal generation of inflammatory molecules. Given that inflammation is a recognized inducer of oxidative stress, a synergistic interaction occurs between the two processes after a heavy meal, with consequent amplification of harmful postprandial effects. The sustained and marked increase in steady-state levels of ROS contributes significantly to the pathogenesis of T2DM and IR. Therefore, a pro-oxidant environment leads to mitochondrial dysfunction, ER stress, activation of NADPH oxidase (NOX) and superoxide (O 2 − ) production. The increase in O 2 − production activates the five major pathways involved in the pathogenesis of diabetes complications: enhancement of the polyol pathway, increased formation of advanced glycation end products (AGEs), increased expression of AGEs receptor and its activating ligands, activation of protein kinase C (PKC) isoforms, and overactivity of the hexosamine pathway [ 55 , 56 , 57 ]. Through these pathways, increased intracellular ROS causes defective angiogenesis in response to ischemia, activates a number of proinflammatory pathways, and cause long-lasting epigenetic changes which drive persistent expression of proinflammatory genes even after glycemia is normalized [ 58 ]. Additionally, increased blood levels of FFAs also lead to mitochondrial dysfunction through two different mechanisms: (1) FFA metabolism by-products disturb the electron flow throughout the mitochondrial respiratory chain and (2) through the incorporation of FFAs into the mitochondrial membranes, thus likely favoring electron leakage [ 59 ]. PHYSICAL ACTIVITY Reduced physical activity and exercise training, and increased sedentary behaviors constitute a link between obesity and T2DM and are associated with increased markers of chronic low-grade systemic inflammation [ 60 , 61 ]. In this condition, proinflammatory molecules are released into the bloodstream and within specific tissues such as interleukin 6 (IL-6), C-Reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α) or IL-1 induces an inflammatory state known as metabolic inflammation [ 37 ]. Indeed, IL-1 is involved in the autoimmune response to β-cells in the pancreas, inhibition of β-cell function and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor, thus inhibiting β-cell function and promoting apoptosis [ 32 ]. Preclinical data suggest that inflammation resolution could prevent the development of T2DM in obesity and prediabetes, which was substantiated by preclinical animal data showing that deletion of the macromolecular complex NLRP3 inflammasome, responsible for the production of IL-1β and IL-18, resulted in improved insulin sensitivity [ 62 ]. Intentional weight loss remains the cornerstone therapy to improve insulin sensitivity and in some circumstances to prevent the incidence of T2DM in individuals with obesity and prediabetes [ 63 ]. Regular exercise and increased physical activity enhance the production of anti-inflammatory cytokines such as IL-1 Receptor antagonist (IL-1Ra) and soluble TNF receptor (s-TNF-R) that are antagonists of IL-1 and TNF-α, respectively. Individuals with increased physical activity also show reduced circulating levels of IL-6, IL-18 and CRP, together with lower levels of leptin, a molecule associated with CRP [ 64 ]. Physical exercise can improve T2DM-inducing oxidative stress by inducing the synthesis of antioxidants such as glutathione (GSH), a major non-enzymatic antioxidant [ 65 ] and other antioxidant enzymes which lead to a long-term reduction in free radical levels [ 32 ]. Finally, irisin is an exercise-regulated myokine, which improves glucose tolerance [ 66 ] secreted by skeletal muscle [ 67 ] and adipose tissue [ 57 ] in response to exercise [ 68 ]. T2DM patients have been found to have lower circulating levels of irisin compared to control subjects. Additionally, diabetic patients with CVD had significantly lower serum irisin than non-CVD patients [ 69 ]. Low levels of serum irisin have been associated with 1.6 times increased risk of CVD incidence in T2DM patients [ 70 ]. GUT DYSBIOSIS Gut microbiota is composed of many microbial species that impact human physiology and participate in different biological processes [ 71 ]. They can modulate the immune system and inflammatory response, regulate gut barrier integrity and human metabolism, take part in the synthesis of metabolites. Gut resident microorganisms produce many metabolites that contribute to physiology in healthy individuals. However, changes due to both inherited and acquired factors such as age, nutrition, lifestyle, genetic predisposition, or underlying diseases can affect the gut microbiota produced metabolite proportion leading to metabolic disturbances that can culminate in disease [ 72 , 73 , 74 ]. The better understating of gut microbiota has evidenced its important role in the development of diabetes and recent studies indicate that changes in dysbiosis can promote IR and T2DM [ 75 ]. A high-fat diet can induce up to threefold lipopolysaccharide (from Gram-negative bacteria) production in mice models, thereby contributing to low-grade inflammation and insulin resistance [ 76 , 77 ]. Furthermore, intestinal dysbiosis can reduce short-chain fatty acid synthesis that promotes gut barrier integrity, pancreatic β-cell proliferation and insulin biosynthesis [ 78 , 79 ]. Dysbiosis can also compromise the production of other metabolites such as branched aminoacids and trimethylamine thus disrupting glucose homeostasis and triggering T2DM development [ 80 , 81 ]. Understanding the clinical implications of the gut microbiome is a relatively new field, and requires further research to better elucidate the connection between gut microbiota and T2DM. METABOLIC MEMORY Metabolic memory refers to the persistence of diabetic complications even after maintained glycemic control. This concept arose from the results of multiple large-scale clinical trials, which showed that after diabetes onset, diabetes complications persist and progress even when glycemic control is restored through pharmaceutical intervention [ 82 , 83 , 84 ]. Among them, the UKPDS post-trial study and Steno-2 trial showed that specifically early glycemic interventions prevent diabetic complication and has a marked decrease in CVD endpoints in patients that received either standard or intensive treatment following their diagnosis [ 84 ]. Later on, animal models of diabetes and in vitro cell cultures demonstrated that the initial hyperglycemic period results in permanent abnormalities (including aberrant gene expression) of target organs/cells [ 85 , 86 , 87 , 88 ]. Metabolic memory involves four mechanisms: epigenetics, oxidative stress, non-enzymatic glycation of proteins and chronic inflammation. Epigenetics involves genetic modulation by factors other than individuals’ DNA sequence, and can regulate gene expression and determine which proteins are transcribed [ 89 ]. There are different epigenetic regulation mechanisms: direct methylation of cytosine or adenine residues, covalent modifications of histone proteins, higher-order chromatin structure and non-coding RNAs. Disruptions or imbalances in epigenetic mechanisms can lead to the development of diabetic pathophysiology [ 90 ]. MicroRNAs (miRNAs) are small non-coding RNA sequences synthesized as non-mature molecules that undergo several processing steps both in the nucleus and in the cytoplasm to become fully matured miRNAs. Once matured, miRNAs bind to their target gene’s mRNA, leading to mRNA silencing or degradation [ 91 ]. Increasing evidence highlights the importance of miRNA mediated post-transcriptional regulation in different aspects of β-cell biology such as cell differentiation, cytokine and growth factor-mediated signaling, glucose metabolism and insulin synthesis and secretion [ 92 ]. Deregulation of miRNA expression can directly impair β-cell function leading to the development of T2DM [ 93 ]. To date, more than 2600 miRNAs have been described within the human genome (miRBase, v.22.1), and multiple miRNAs have been shown to be involved in the pathogenesis of T2DM, including miR-200, miR-7, miR-184, miR-212/miR132 and miR-130a/b/miR-152 [ 94 ]. For instance, overexpression of miR-7 results in reduced insulin secretion via inhibition of genes involved in vesicle fusion and SNARE activity such as Snca, Cspa and Cplx1 [ 95 ]. In the case of miR-375, over-expression results in impaired exocytosis and thereby reduced insulin secretion. Conversely, it is the downregulation of miR-375 expression that causes a reduction in β-cell mass [ 93 , 96 , 97 ]. Several studies have evidenced that deregulation of the microRNA (miRNA) profile (post-translational histone methylation and non-canonical histone variant inclusion in octomers) may persist even after normoglycemia restoration [ 98 , 99 , 100 , 101 ]. MiRNAs participate in metabolic memory by targeting the mRNA of genes encoding enzymes involved in DNA methylation and those tightly regulated at the level of promoter methylation, transcription, and processing [ 102 ]. It has been shown that high glucose levels can alter post-translational histone modifications (PTHMs) and the activity of DNA methyltransferases generating irreversible changes that explain the long-term harmful effects of metabolic memory [ 103 , 104 , 105 , 106 ]. Hyperglycaemia induces an excess of ROS generation by mitochondria, which gives rise to diabetes complications [ 107 ] that may persist even when hyperglycemia is controlled. The damage following hyperglycemia-induced oxidative stress can be prevented when good glycemic control is initiated very early, but is not easily reversed if poor control is maintained for a longer duration [ 108 , 109 ]. At the early stages of T2DM, there is a relationship between hyperglycemia, increased oxidative stress, and excessive AGE formation. As the disease progresses, there is persistent protein glycation of the components of the respiratory chain that together with mitochondrial DNA damage can generate a hyperglycemia-independent concatenation of events leading to a synergy between oxidative stress and AGEs [ 86 ]. The effects of this metabolic imbalance activate inflammatory processes through receptor binding of AGEs or ROS which can modify the composition and structure of the extracellular matrix [ 98 ]. These structural changes may cause endothelial dysfunction and then atherosclerosis [ 98 ]. Finally, low-grade inflammation, which is involved in T2DM development and its vascular complications, has been shown to mediate metabolic memory. Many environmental factors (age, obesity, sedentarism and diet) that promote T2DM development trigger an inflammatory response leading to IR and endothelial dysfunction [ 105 , 110 , 111 ]. Obesity leads to NF-κB activation, which mediates the expression of inflammatory genes, which enhances monocyte binding to endothelial and vascular smooth muscle cells, subsequently promoting monocyte-to-macrophage differentiation [ 105 ]. In addition, NF-κB activation induces expression of inflammatory cytokines that are involved in vascular inflammation, with subsequent generation of endothelial adhesion molecules, proteases, and other mediators [ 111 ]. Another important factor that links inflammation and oxidative stress in obesity condition is the Toll-like receptor, which contributes to hypertension, insulin resistance, and obesity [ 105 ]. In summary, T2DM is a heterogeneous and progressive disorder that represents a series of metabolic conditions associated with hyperglycemia and caused by defects in insulin secretion and/or insulin action due to a complex network of pathological conditions. There are many different paths, driven by various genetic and environmental factors, that interact and mutually reinforce each other leading to an increased risk of other diseases including heart, peripheral arterial and cerebrovascular disease, obesity and nonalcoholic fatty liver disease, among others. The complex network of pathological conditions leading to T2DM development are summarized in Figure 2 . MITOCHONDRIAL DYSFUNCTION There is increasing evidence associating mitochondrial dysfunction with T2DM development, age-related IR and T2DM complications [ 112 ]. Indeed, oxidative stress, defective mitochondrial biogenesis, genetic mutations affecting mitochondrial integrity and aging promote mitochondrial dysfunction and are closely associated with T2DM development ( Figure 3 ) [ 113 , 114 ]. The main function of mitochondria is ATP synthesis through oxidative phosphorylation in response to metabolic demand [ 115 ]. Mitochondria also participate in the production of different metabolites used as precursors of several macromolecules (lipids, proteins, and DNA). In addition, mitochondria play an important role in maintaining ion homeostasis, ROS clearance, the stress response, and serve to integrate multiple signaling pathways [ 116 , 117 ]. An imbalance between energy intake and expenditure in the mitochondria generates mitochondrial dysfunction, a state characterized by a reduced ratio of energy production to respiration [ 112 ]. Under these circumstances, nutrient oxidation efficiency is reduced leading to a decreased ratio of ATP synthesis/oxygen consumption, which increases O 2 − production [ 118 ]. In fact, the accumulation of ROS in the mitochondria is one proposed mechanism linking mitochondrial dysfunction to IR [ 119 ]. This relationship was corroborated in studies showing decreased mitochondria oxidative capacity in skeletal muscle and impaired lipid metabolism in obese and insulin-resistant individuals compared to healthy controls [ 120 , 121 , 122 ]. In addition, patients with T2DM have been found to have downregulation of genes involved in oxidative metabolism that are regulated by the peroxisome proliferator-activated receptor γ co-activator 1α (PGC 1α) [ 123 , 124 ] and a diminished phosphocreatine re-synthesis rate, both indicative of impaired mitochondrial function [ 125 ] ( Figure 3 ). Moreover, some relatives of T2DM patients have been found to have decreased mitochondrial respiration suggesting that mitochondrial dysfunction may precede T2DM development. It has also been proposed that T2DM development may be a direct consequence of defects in the oxidative phosphorylation system and the electron transport chain (ETC) rather than a decrease in mitochondrial content [ 126 ]. The generation of ROS is highly implicated in the relationship between mitochondrial dysfunction and insulin resistance. ROS production takes place mainly at complex I and complex III of the ETC and increases when ETC is not able to handle excessive electron input. In these circumstances, as a consequence of nutrient overload, electron supply to the mitochondrial ETC increases and the electron excess is transferred to oxygen generating O 2 − and subsequent hydrogen peroxide [ 127 ]. ROS generated in mitochondria oxidize the Cys and Met residues in proteins, damaging protein structure, impairing their function and eventually causing cell death. ROS species also damage DNA and membrane lipids, thus promoting mitochondrial dysfunction [ 128 ]. In addition, ROS overproduction activates the polyol pathway, the formation of AGEs, and the expression of the AGEs receptor and its activating ligands. It also activates PKC isoforms and upregulates the hexosamine pathway contributing to T2DM worsening [ 129 , 130 ]. In sum, excessive ROS generation by mitochondria contributes to accelerated T2DM progression ( Figure 3 ). Mitochondrial dysfunction includes a reduction in mitochondrial biogenesis, along with a decrease in the expression of mitochondrial oxidative proteins, such as ETC complexes, which leads to decreased substrate oxidation. The damage produced by high oxidative stress in the mitochondria activates mitophagic processes in order to eliminate dysfunctional mitochondria or in case of excessive cellular stress to apoptosis [ 131 ]. These two processes reduce substrate utilization and enhance the accumulation of lipid intermediates such as diacylglycerols (DAG) and ceramide (CER) that disrupt the insulin signaling pathway [ 132 ]. DAG induces an increment of the serine/threonine phosphorylation of IRS-1, reducing its insulin-stimulated tyrosine phosphorylation and downstream propagation of the insulin signaling pathway [ 133 ] while CER inhibits protein kinase AKT [ 133 ]. The accumulation of DAG and CER contributes to the mitochondrial dysfunction seen in IR ( Figure 3 ). Defects in mitochondrial biogenesis may be mediated by the downregulation of PGC 1α that has also been detected in T2DM patients [ 123 , 124 ]. PGC 1α is a transcription coactivator that regulates the expression of key genes involved in mitochondrial biogenesis, adaptive thermogenesis and metabolic substrate metabolism [ 134 ]. Furthermore, some of the genes involved in oxidative metabolism that are downregulated in individuals with T2DM are under the control of PGC 1α [ 124 ]. Mitofusin-2 , a key driver in mitochondria biogenesis is also downregulated in humans with T2DM [ 135 ]. Interestingly, mitofusin-2 levels increase upon weight loss indicating that nutrient and energy oversupply leads to mitochondrial dynamics defects [ 135 ]. Mitochondrial homeostasis is maintained via mitochondrial biogenesis and the selective clearance of damaged organelles. Mitochondrial dynamics are crucial to maintaining healthy mitochondria and control their quantity. Mitochondria fission promotes the removal of damaged mitochondria in a process known as mitophagy, which has to be efficiently and tightly regulated in order to preserve cell homeostasis [ 136 ]. Thus, mitophagy is considered to be one of the core mechanisms controlling the mitochondrial quantity and quality [ 137 ]. The process of removing damaged mitochondria consists of two steps: the induction of general autophagy and the priming of damaged mitochondria for selective autophagy recognition [ 138 ]. Once the degradation process is completed, the products are released back into the cytosol where macromolecular constituents are recycled. This process generates energy to maintain cell viability under unfavorable conditions and protects the cell during stress conditions [ 136 , 139 ]. When mitophagy is impaired, cellular stress and ROS production increase contributing to reduced hepatic insulin sensitivity and glucose homeostasis, two of the major pathological branches of T2DM development [ 112 , 140 ]. Deregulation of mitochondria dynamics with a shift towards fission promotes metabolic dysfunction as demonstrated by the onset of obesity and IR following the ablation of fusion protein in mice [ 141 , 142 ]. Furthermore, increased mitochondrial fission and mitochondrial fragmentation have been associated with mitochondrial depolarization, impaired ATP production and decreased insulin-dependent glucose uptake as well as increased mitochondrial ROS and impaired insulin signalling in C2C12 murine cell line and cybrids, respectively [ 143 , 144 ]. These studies highlight that the deleterious effect of unbalanced mitochondrial dynamics on metabolic health. Enhanced mitochondria fission also negatively impacts fatty acid β-oxidation, which is a pivotal metabolic defect in obesity and IR [ 120 , 121 ] contributing to the accumulation of lipotoxic lipid species. Fusion-shifted mitochondria dynamics has been also associated with an increase in fatty acid utilization putatively preventing lipotoxicity [ 145 ]. The role of mitochondrial genetics in the risk of T2DM has been clearly established. Indeed, several mtDNA variants (homoplasmic or heteroplasmic) have been associated with T2DM development. To date, the group of heteroplasmic variants associated with a higher risk of T2DM development includes A3243G, T14577C and A5178C [ 146 , 147 , 148 , 149 ]. The group of homoplasmic variants associated with T2DM risk includes C1310T, G1438A, A12026G, T16189C and A14693G [ 150 , 151 , 152 ]. It is important to note that additional studies are necessary to determine whether more metabolically active tissues that generate more mitochondrial ROS have increased rates of mtDNA heteroplasmy in T2DM. To summarize, there is a highly nuanced and bi-directional relationship between mitochondrial dysfunction and T2DM. On one hand, aspects of T2DM such as insulin resistance can lead to mitochondrial dysfunction, such as through nutrient overload leading to ROS accumulation. On the other hand, mitochondrial dysfunction may predispose patients to subsequently developing T2DM, as evidenced by the presence of mtDNA variants associated with T2DM. Additional research is needed to better characterize the relationship between mitochondrial health and diabetes. 5. INSULIN RESISTANCE IR refers to a decrease in the metabolic response of insulin-responsive cells to insulin or, at a systemic level, an impaired/lower response to circulating insulin by blood glucose levels [ 153 ]. There are three broad categories of IR or insulin-deficient conditions: (1) diminished insulin secretion by β-cells; (2) insulin antagonists in the plasma, due either to counter-regulatory hormones or non-hormonal bodies that impair insulin receptors or signaling; and (3) impaired insulin response in target tissues [ 154 ]. The action of insulin is influenced by the interplay of additional molecules including growth hormone and IGF-1 in the fed state. While fasting, the insulin response is mitigated by glucagon, glucocorticoids and catecholamines in order to prevent insulin-induced hypoglycemia. The ratio of insulin/glucagon plays a major role in this regulation, since it determines the relative degree of phosphorylation of downstream enzymes in the regulatory signaling pathways. While catecholamines promote lipolysis and glycogenolysis, glucocorticoids promote muscle catabolism, gluconeogenesis and lipolysis. Hence, excessive secretion of these hormones may be responsible for inducing IR [ 155 , 156 ]. Regarding the last category, there are three main extra-pancreatic insulin-sensitive organs that play major roles in the aforementioned processes: skeletal muscle, adipose tissue and liver. A defective action of insulin in these tissues often precedes the development of systemic IR, thus progressively leading T2DM. Skeletal muscle IR is considered to be the most important extra-pancreatic factor in the development of T2DM [ 157 ]. Under physiological conditions, insulin stimulates muscle glycogen synthesis by enhancing glucose uptake from plasma. There are three primary rate-limiting factors implicated in glucose uptake and glycogen synthesis: glycogen synthase, hexokinase and the glucose transporter GLUT4 [ 158 ]. Upon insulin binding to insulin receptor (INSR) in muscle cells, GLUT4 translocates from intracellular compartments (early endosomes (EE), endosomal recycling compartment (ERC) and trans-Golgi network (TGN)) to the plasma membrane. This process allows glucose uptake and reduces circulating glucose levels [ 159 ]. Mutations that reduce the expression of insulin receptor or GLUT4, as well as any defect in either upstream or downstream signaling pathway would reduce glucose intake into the muscle resulting in a hyperglycaemic state [ 153 , 160 ]. The activation of INSR tyrosine kinase activity is essential for the action of insulin on glucose metabolism. Insulin binding to the α-subunit of the INSR causes phosphorylation of the β-subunit on multiple tyrosine residues and allows insulin-mediated signaling. Thus, mutations in any of the main phosphorylation sites can impair INSR tyrosine kinase activity, thereby impairing insulin action on skeletal muscle [ 161 ]. As mentioned above, mutations in key proteins of the downstream signaling pathway such as IRS-1 and IRS-2 or phosphoinositide 3-kinase (PI3K) also impair insulin action on the muscle. Apart from mutations or defective epigenetic regulation, environmental factors can also play an important role in glucose uptake by muscle. Physical activity increases blood flow into skeletal muscle cells and thereby enhances glucose utilization [ 32 ]. Obesity, which is associated with chronic inflammation, contributes to IR and T2DM. Increasing evidence suggests that as a consequence of obesity, increased immune cell infiltration and secretion of proinflammatory molecules in intermyocellular and perimuscular adipose tissue leads to skeletal muscle inflammation. This ultimately leads to myocyte inflammation, impaired myocyte metabolism, and contributes to IR via paracrine effects [ 162 ]. 5.2. ADIPOSE TISSUE Adipose tissue is a metabolically dynamic tissue capable of synthesizing a wide range of biologically active compounds that regulate metabolic homeostasis at a systemic level [ 163 ]. Indeed, adipose tissue participates in a broad range of biological processes involving, among others, immunity, coagulation, angiogenesis, fibrinolysis, reproduction, vascular tone control, appetite regulation, body weight homeostasis and glucose and lipid metabolism [ 164 ]. Insulin acts on adipose tissue in two different ways: (1) stimulating glucose uptake and triglyceride synthesis; and (2) suppressing triglyceride hydrolysis and inducing the uptake of FFA and glycerol from circulation [ 165 ]. In the fed state, GLUT4 allows uptake of glucose from the bloodstream into adipocytes, activating glycolysis in which glycerol-3-phospate (glycerol-3-P) is produced and incorporated into lipogenic pathways. Glycerol-3-P, along with the fatty acids coming from VLDLs, are esterified, forming triacylglycerol (TGA) that is stored in lipid droplets. During metabolic stress, TGA droplets the adipocyte are depleted, in order to provide FFA to be used as an energy source in other tissues. An impaired response to insulin stimulation by adipose tissue is known as adipose IR (Adipose-IR). Adipose-IR can lead to impaired suppression of lipolysis, impaired glucose uptake, and enhanced FFA release into plasma even in the presence of high insulin levels [ 166 ]. Among the signaling elements affected by adipose-IR, we found that defective AKT activation impairs GLUT4 translocation to the membrane and promotes the activation of lipolytic enzymes that aggravate hyperglycemia [ 153 ]. Adipose-IR, as mentioned before, is associated with glucose intolerance and elevated release of FFA into a plasma that accumulates in other tissues such as muscle or liver. In the case of the liver, FFA accumulation results in impaired insulin signaling that promotes hepatic gluconeogenesis and impairs the glucose-stimulated insulin response, inducing T2DM development. It has been shown that abnormally increased adipose tissue mass and adipocyte size correlate with pathologic vascularisation, hypoxia, fibrosis and macrophage-mediated inflammation [ 167 ]. A high-fat diet and obesity can activate saturated FFA-stimulated adenine nucleotide translocase 2 (ANT2), an inner mitochondrial protein that results in adipocyte hypoxia and triggers the transcription factor hypoxia-inducible factor-1α (HIF-1α). This culminates in adipose tissue dysfunction and inflammation [ 1 ]. Hypertrophied adipocytes as well as adipose tissue-resident immune cells contribute to increased circulating levels of proinflammatory cytokines. This increase in circulating proinflammatory molecules, together with an increase in local cytokine releases such as TNF and IL-1β and IL-6 facilitates the emergence of a chronic state of low-grade systemic inflammation, also known as metabolic inflammation [ 1 ]. This chronic inflammatory state is considered to be a key part in the pathogenesis of IR and T2DM [ 168 ]. The insulin stimulation effects on healthy and hypertrophic adipose tissue are shown in Figure 4 . 5.3. LIVER In the liver, insulin does not only regulate glucose production/utilization but also affects lipid metabolism more broadly. When circulating glucose levels increase and insulin is secreted by pancreatic β-cells, insulin binding to liver INSR induces autophosphorylation of the receptor. Consequently, insulin receptor substrates (IRSs) are recruited and phosphorylated. In turn, IRSs activate PI3K, which phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2), generating phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 then activates PDK1, which phosphorylates AKT. In addition, AKT is phosphorylated by mTORC2. Once AKT is fully activated, it participates in several downstream pathways that regulate multiple metabolic processes including glycogen synthesis, gluconeogenesis, glycolysis and lipid synthesis [ 169 ]. In physiological states, the combined action of glucagon and insulin allows the precise regulation of hepatic glucose output. While glucagon induces hepatic glucose production, insulin acts as a potent inhibitor of glucose production when its concentration in the blood is elevated [ 170 ]. The effect of insulin on hepatic glucose production is due to both direct and indirect mechanisms. However, the relative importance of each of these mechanisms remains unclear [ 171 ]. In addition to inducing glycogen synthesis, insulin also inhibits hepatic glucose production by activating FOXO1, resulting in a reduction of hepatic glucose release. FOXO1 is a transcription factor that belongs to a subclass of the forkhead family of transcription factors that possess a forkhead box-type DNA binding domain. FOXO1 recognizes a specific regulatory element termed the insulin response element (IRE) on the promoters of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) genes, both of which play important roles in maintaining glucose level in states of starvation [ 172 , 173 , 174 ]. Thus, through inhibition of FOXO1, insulin promotes glucose storage as glycogen and inhibits glucose synthesis and hepatic glucose output [ 175 ] ( Figure 5 ). Similar to the case in insulin-sensitive tissues, in states of IR, physiologic levels of circulating insulin are insufficient to elicit the appropriate insulin response in hepatic cells [ 176 ]. In the liver, IR impairs glycogen synthesis, fails to suppress glucose production, enhances lipogenesis, and increases the synthesis of proteins such as the proinflammatory CRP. In fact, the abnormal production of proinflammatory proteins such as adipocytokines and cytokines, combined with conditions such as oxidative stress, can lead to an inflammatory state responsible for altered insulin response by the liver [ 175 ]. 6. T2DM OUTCOMES/COMPLICATIONS: CARDIOVASCULAR RISK As described in the previous sections, T2DM is a multisystem disease with a strong correlation with CVD development [ 177 ]. T2DM leads to a two- to four-fold increase in the mortality rate of adults from heart disease and stroke and is associated with both micro- and macro-vascular complications, the latter consisting of accelerated atherosclerosis leading to severe peripheral vascular disease, premature coronary artery disease (CAD) and increased risk of cerebrovascular diseases [ 178 , 179 , 180 ]. These factors lead to T2DM being considered a significant risk factor for CVD [ 181 ], likely through the involvement of several molecular mechanisms and pathological pathways. These include the role of IR in atherosclerosis, vascular function, oxidative stress, hypertension, macrophage accumulation and inflammation [ 182 , 183 , 184 , 185 ]. The following sections describe in detail the main factors implicated in cardiovascular risk outcomes from T2DM and the interactions between them ( Figure 6 ). Dyslipidaemia is a common feature of T2DM, and increases the incidence of atherosclerosis and mortality of diabetic patients [ 186 ]. The hallmark of diabetic dyslipidemia is a characteristic dyslipidaemic profile consisting of elevated TG, TG-rich lipoproteins (TRLs), small dense LDLs (sdLDL), and reduced HDL levels [ 187 , 188 , 189 ]. Although the pathophysiology of dyslipidemia in T2DM is not completely characterized, several factors such as hyperglycemia, insulin resistance, hyperinsulinemia, abnormalities in adipokines and adipocytokines have been implicated [ 190 ]. Epidemiological studies indicate that TG-rich lipoproteins and their remnants contribute to atherogenesis and CVD risk [ 191 , 192 , 193 , 194 , 195 ] and experimental studies indicated a connection between cholesterol deposition and inflammation as a result of TRLs entry into the artery wall [ 196 , 197 ]. TRLs consist of a great variety of nascent and metabolically modified lipoprotein particles including intestine-derived apoB48 (chylomicrons and chylomicron remnants) and liver-derived apoB100 (VLDL and its remnants). TRLs are highly heterogeneous in size, density, and apolipoprotein composition [ 198 ]. Under physiological conditions, chylomicrons deliver dietary lipids and lipid-biliary sources to the liver, which upon entering central circulation acquire apoE, apo-CI, apo-CII and apo-CIII from circulating HDL ( Figure 7 ). Apo-CII, an activator of lipoprotein lipase (LPL), hydrolyzes TG within the chylomicron core, thereby releasing free fatty acids (FFAs). The progressive removal of TGs leads to the formation of chylomicron remnants (CR), which upon apoE incorporation, are cleared by hepatocytes ( Figure 7 ). This, together with the uptake of FFA generated by lipolysis in adipose tissue provides the major source of hepatic VLDL assembly and secretion. Once in the circulation, VLDL particles incorporate apo-CII and apoE from HDL allowing VLDL to be progressively lipolyzed leading to the generation of smaller VLDL particles (VLDL1, VLDL2 and VLDL3), IDL, and finally LDL ( Figure 7 ). Lipoprotein production, metabolism, and clearance are efficient processes. However, T2DM and IR are among the most important metabolic derangements in these process and they give rise to impaired metabolism and clearance of chylomicrons and VLDLs [ 199 , 200 ]. Increased hepatic TG content present in T2DM patients leads to elevated hepatic production of VLDL and normal or slightly elevated LDL-C levels, most commonly sdLDLs enriched in TG [ 189 , 201 ]. One of the primary abnormalities in IR is impaired adipose tissue fat storage, resulting from insulin’s inability to inhibit hormone-sensitive lipase (HSL). This results in constitutive FFA release from the intracellular TG stores of adipocytes. The released FFAs are taken up by hepatocytes, where they can be directed to the mitochondria and undergo β-oxidation; be re-assimilated into TG to assemble new VLDL particles; shifted to gluconeogenesis resulting in a worsening of hyperglycemia; or stored as TG leading to hepatic steatosis. The dominant feature of diabetic dyslipidemia is the increased production rate of VLDL-apoB100 by the liver, mainly VLDL1, which is related to insulin sensitivity indices [ 202 ]. This highlights the role of insulin on VLDL assembly and secretion by hepatocytes [ 203 ]. Insulin plays a role in almost all the steps of VLDL assembly and secretion. It is known that insulin inhibits the transcription of Mttp, the gene coding for the microsomal transfer protein (MTP), the protein responsible for assembling TG with apoB100 [ 204 ]. MTP facilitates concerted lipid transfer and apoB100 folding as it enters the ER lumen and lipidation determines the amount of the active pool of apoB100 [ 205 ]. Lipidation of apoB100 is a co-translational event and a rate-limiting step of apoB100 mRNA stability thus low availability of TG leads to apoB100 degradation. The addition of TG to apoB100 generates nascent VLDL particles that are transported to the GA by Sar2/COPII-containing vesicles. Within the GA, VLDL maturation occurs in a process promoted by the phospholipase D1 (PLD1) [ 203 ]. Therefore, in insulin-resistant condition, MTP expression and activity is increased thus contributing to raising apoB100 lipidation and to its rescue from degradation. Indeed, IR leads to a loss of the acute insulin-mediated inhibition of apoB100 secretion [ 205 ]. Availability of TGs within hepatocytes is important for VLDL synthesis [ 206 ] and the liver uses both de novo synthesized FAs and extra-hepatic FFAs as a substrate for TG synthesis [ 207 ]. De novo lipogenesis occurs primarily in the fed state in which the expression of lipogenic genes is regulated by the sterol regulatory element-binding protein (SREBP). The SREBP-1c isoform up-regulates almost all the enzymes involved in FA synthesis as well as enzymes that supply acetyl-CoA units and reducing equivalents to the pathway [ 208 ]. Insulin regulates SREBP-1c, which explains the lipogenic effect of chronic hyperinsulinemia [ 208 ]. FFAs derived from adipose tissue is also a major source of liver TGs and VLDL production. As mentioned above, T2DM is characterized by increased production of FFAs by adipose tissue [ 207 ]. Therefore, in IR, an increase in TG lipolysis in adipose tissue and FFA influx serves as another source of lipid to the liver [ 207 ]. As mentioned above, in the IR milieu, insulin has reduced capacity to inhibit VLDL secretion in the fed state, the availability of apo-CII is lower and apo-CIII production is increased [ 209 ]. These events result in the accumulation of VLDL remnants and IDL due to diminished clearance of TRLs by hepatocytes [ 210 ]. Additionally, hepatic IR also impairs LRP1 translocation from intracellular vesicles to the hepatocyte plasma membrane, which contributes to impaired clearance of TRLs [ 211 , 212 ] ( Figure 7 ). In an effort to offload TG from remnant lipoproteins (VLDL 2+3 and IDL; RLPs), CETP is activated and promotes an exchange of TG out of RLPs and incorporates CE from HDL and LDL particles [ 213 ]. The TG-enriched HDL and LDL particles are better substrates for lipolysis by hepatic lipase leading to reduced levels of circulating HDL-C and an increase in sdLDL particles, which are more atherogenic [ 214 ]. The increased movement of CE into circulating TRLs mediated by enhanced activity of CETP [ 215 ] plays a key role in generating small dense HDL and LDL particles, the former being less atheroprotective and the latter more atherogenic [ 216 ]. TG enrichment of HDL enhances circulating HDL clearance [ 217 ]. The lower HDL concentration and modified composition of HDL have an important impact in diminishing the particle capacity of inducing cholesterol efflux from the cells, which is the first step in reverse cholesterol transport (RCT) [ 218 ]. The impaired RCT activity has been associated with increased risk of CAD [ 219 ] and with flow-mediated vasodilation in T2DM patients [ 220 ]. Atherosclerosis is accelerated by the increased permeability of sdLDL into the subendothelial space ( Figure 7 ) [ 221 , 222 ]. SdLDL particles are characterized by a lower affinity for LDLR due to conformational rearrangements occurring in apoB100 as the particle decreases in volume and size [ 223 ]. Furthermore, sdLDL particles are more susceptible to oxidation and thus avidly scavenged by activated macrophages in the subendothelial space, giving rise to foam cells [ 224 ]. In addition, sdLDL particles show increased proteoglycan binding and facilitated entry into the arterial wall, increased arterial retention, and a longer half-life [ 225 ]. sdLDL particles are also more likely to be glycated, more resistant to breakdown, and more susceptible to oxidation by free radicals [ 226 ]. There is an insulin response element in the gene for apoA-I, the primary apolipoprotein constituent of HDL particles [ 227 , 228 ]. As the liver becomes more insulin resistant, less apoA-I is produced and there is less HDL biogenesis. Adipocytes express the ATP-binding membrane cassette transport protein A1 (ABCA1). IR downregulates the expression of ABCA1 on the surface of adipocytes and reduces HDL formation by these cells [ 229 , 230 , 231 ]. Chylomicrons are enriched with apoA-I. IR reduces the release of this apoA-I into the serum by inhibiting LPL. In addition, within the milieu of IR of diabetes, HDL particle concentrations are not only quantitatively reduced, but also tend to be dysfunctional and unable to perform their primary functions, including reversal of cholesterol transport and inhibition of oxidative and inflammatory phenomena [ 232 ]. This highly atherogenic lipid profile is a pivotal contributor to atherogenic dyslipidemia, which is causally linked to the development and progression of atherosclerotic CV disease (ASCVD) [ 233 , 234 ]. The relationship between atherogenic dyslipidemia and ASCVD is supported by prospective longitudinal cohorts, clinical evidence and genetic linkage studies. As an example, the best predictor of risk of myocardial infarction at the population level in the INTERHEART study was the apolipoprotein (apo) B100/apoA-I ratio, reflecting the correlation between all apoB (atherogenic lipoproteins) and HDL (representing classically anti-atherogenic particles) [ 235 ]. The relationship between atherogenic dyslipidemia and ASCVD has also been demonstrated in prospective randomized clinical trials using statins. Even when treated with statins, patients with the atherogenic dyslipidemia phenotype have a higher risk of CV events than those without AD [ 236 , 237 ]. Diabetic dyslipidemia acts in concert with other metabolic and vascular abnormalities to further compound vascular risk. Chronic hyperglycemia induces endothelial dysfunction through a variety of mechanisms such as by reducing vasodilation, increasing vasoconstriction, increasing exposure to free radicals and impairing endothelial cell function, with a net effect of facilitating pro-atherogenic conditions [ 238 ]. Increased activity of the renin-angiotensin axis has also been found to further increase oxidative stress [ 239 ]. 6.2. IMPAIRED ENDOTHELIAL FUNCTION AND ATHEROSCLEROSIS DEVELOPMENT Endothelium plays an important role in the regulation of vascular tone and structure through a balanced release of endothelial-derived relaxing and contracting factors. This balance is altered in T2DM leading to alteration of the physicochemical properties of the vascular wall via endothelial dysfunction, oxidative stress, platelet hyperreactivity, and inflammation [ 240 , 241 ]. These abnormalities lead to enhanced vasoconstriction, development of atherosclerosis, and favored thrombus formation [ 179 , 180 ]. Vascular endothelial cells are particularly susceptible to developing intracellular hyperglycemia because glucose diffuses passively through their plasma membrane. In T2DM, the excess of glucose can be metabolized in the sorbitol pathway to sorbitol and fructose by aldose reductase, which activates the aldose reductase secondary metabolic pathway, with concomitant oxidation of NADPH to NADP + and reduction of NAD + to NADH. NADPH depletion and an increased NADH/NAD + cytosolic ratio leads to a change in redox potential that accelerates glycolysis and increases de novo synthesis of DAG [ 242 ]. As a result, protein kinase C (PKC) is activated, nitric oxide (NO) is reduced. These effects cause vascular permeability and increase contractility. Simultaneously, the increased NADH/NAD + ratio also results in higher production of O 2 − , LDL oxidation, cytotoxic effects on endothelial cells and reduced NO availability, leading to endothelial dysfunction [ 241 , 242 ]. The overproduction of aldoses by the sorbitol pathway promotes protein glycosylation that yields the formation of the stable Amadori products (such as glycosylated hemoglobin) and AGEs. AGEs are associated with several molecules that augment oxidant activity and consequently the production of ROS, which increases oxidative stress and prevents the release of NO, resulting in vascular lesions. AGEs may also reduce endothelium-derived NO bioavailability and activity, further compromising vascular activity [ 243 ]. In addition, AGEs can trigger an inflammatory and pro-coagulant state and can cause endothelial activation through the induction of receptor-mediated gene transcription. AGE binding to the RAGE-receptor, nuclear transcription factor NF-κB [ 242 , 243 ] is activated leading to transcription of endothelin-1, VCAM-1, ICAM-1, E-selectin, thrombomodulin, TF, vascular endothelial growth factor (VEGF), IL-1, IL-6, and TNF-α [ 242 , 244 ]. Increased expression of inflammatory and adhesion molecules amplifies the inflammatory response and aggravates diabetic vascular complications. These pro-inflammatory cytokines stimulate the expression and release of pro-coagulant molecules and inhibit the expression of anti-coagulant molecules by endothelial cells [ 245 ]. This leads to a pro-coagulant state in the surface of the endothelium and increases growth factor production resulting in a thickening of the basement membrane, thus favoring protein and lipid deposition and impairing vasodilation [ 242 , 246 ]. 6.2.2. ENDOTHELIAL DYSFUNCTION IN T2DM AND ATHEROSCLEROSIS DEVELOPMENT Hyperglycemia-associated vascular injury, oxidative stress, inflammation and altered hemodynamic balance may initiate atherosclerosis development and formation of arterial thrombus [ 247 ]. At early stages of atherosclerosis, circulating LDL binds to matrix proteoglycans where their oxidation is favored, giving rise to highly pro-inflammatory particles that stimulate the expression of several adhesion molecules by endothelial cells [ 242 , 248 ]. This promotes selective binding of leukocytes and their transmigration into the vascular wall along with recruitment and activation of circulating monocytes that differentiate into macrophages. The excess of oxidized LDL is removed by macrophages by a non-regulated mechanism that leads to the formation of foam cells and the onset of fatty streaks. Mononuclear cells release inflammatory cytokines, including IL-1 and IL-6, promoting the recruitment of additional inflammatory cells. As a result, smooth muscle cells proliferate and migrate into the intima where they synthesize and secrete extracellular matrix facilitating fibroatheroma formation [ 242 ]. As the process progresses, if a fissure or ulceration of the plaque occurs, highly thrombogenic substances are exposed leading to adhesion and aggregation of platelets, which promotes thrombus formation [ 249 ]. In addition, platelets can also release pro-inflammatory cytokines and growth factors promoting monocyte recruitment to atherosclerotic plaques, which stimulates fibroblasts and smooth muscle cell proliferation thus accelerating the atherosclerotic process. 6.3. DIABETES-ASSOCIATED CHRONIC INFLAMMATION AND ATHEROSCLEROSIS PROGRESSION A critical component of T2DM is a chronic low-grade inflammatory state, referred to as “metaflammation” [ 250 ]. This chronic condition involves the same cellular and molecular players of acute inflammatory responses and has been suggested as an underlying cause of the progression of atherosclerosis in T2DM. Hyperglycaemia can increase circulating cytokines that can lead to chronic inflammation in T2DM [ 250 ]. Among them, patients with T2DM have higher levels of IL-1b, IL-6, IL-8, MCP-1, and other major cytokines in both monocytes and macrophages [ 130 ]. The underlying mechanisms involved in this process are ROS-mediated activation of p38 and other proinflammatory kinases, upregulation of NF-kB induction, oxidative stress, and activation of the AGE-RAGE pathway [ 129 , 130 ]. In addition, exposure to high glucose levels impairs the phagocytic activity of macrophages, which partially explains the increased incidence of chronic infection among T2DM patients [ 251 ]. Indeed, T2DM is associated with increased activity of the inflammasome, upregulation of the nucleotide-binding oligomerization domain-like receptor 3 (NLRP3), increased levels of IL-1β and IL-18 [ 252 , 253 , 254 ]. These events trigger neutrophil extracellular trap activation, or NETosis, a characteristic cell death of macrophages causing chronic inflammation [ 255 ]. High levels of these markers have been found in T2DM patients [ 256 ], which are enhanced in hyperglycaemic conditions [ 257 ]. 6.4. ADIPOKINE BALANCE AND CVD RISK Adipose tissue dysfunction as a result of T2DM can result in an imbalance between pro-inflammatory and anti-inflammatory adipokines, and is one of the mechanisms of T2DM complications. Several studies indicate that adipokines are related to IR, and can result in endothelial dysfunction, and pro-inflammatory and pro-atherogenic states [ 258 , 259 ]. Adiponectin is a well-described insulin-sensitizing hormone and its expression and circulating levels are inversely proportional to the extent of adiposity. Adiponectin has insulin-sensitizing properties [ 260 , 261 ]. Adiponectin acts through ADIPOR1 and ADIPOR2 receptors [ 262 ] and the peroxisome proliferator-activated receptor α (PPARα) pathway, leading to decreased hepatic gluconeogenesis, increased liver and skeletal muscle fatty acid oxidation, increased glucose uptake in skeletal muscle and white adipose tissue, and decreased white adipose tissue inflammation [ 263 ]. In addition, adiponectin ameliorates β-cell death by neutralizing inflammatory and lipotoxic ceramides and DAGs [ 264 ] and shows strong anti-inflammatory effects on other cell types such as macrophages and fibrogenic cells [ 263 , 265 , 266 ]. Low concentrations of adiponectin have been found in T2DM patients and are correlated with increased risk of developing premature arteriosclerosis, and are thus considered an additional CVD risk factor [ 267 ]. Notably, adiponectin deficiency is associated with coronary artery disease, hypertension, endothelial dysfunction and greater carotid intima-media thickness [ 268 , 269 , 270 , 271 ]. Low concentrations of adiponectin lead to an increased expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, promotes differentiation of macrophages into foam cells and enhances the proliferation and migration of smooth muscle cells [ 272 ]. Omentin is an adipokine secreted from white adipose tissue and is involved in glucose homeostasis [ 273 , 274 ]. Omentin circulates in the blood [ 275 , 276 ], and is associated with reduced levels in T2DM patients [ 277 , 278 ]. In vitro studies have shown that omentin enhances insulin-stimulated glucose uptake in human adipocytes by AKT signaling pathway activation [ 273 ]. In humans, an inverse correlation between omentin levels and IR is seen, both at the protein and mRNA levels [ 277 , 279 , 280 ]. Additional studies show that omentin has anti-inflammatory properties, diminishes cytokine expression [ 281 , 282 ], and is negatively associated with systemic inflammatory markers such as TNF and IL-6 [ 283 ]. Vaspin (visceral adipose tissue-derived serine protease inhibitor) is an adipokine that inhibits proteases responsible for IR and protects against atherosclerosis and plaque development [ 284 , 285 ]. It has been shown that T2DM patients have higher serum vaspin levels than healthy controls. Higher vaspin levels are associated with a 1.7-fold increased risk of CVD [ 70 ]. High vaspin is also associated with increased severity of coronary artery disease [ 286 ]. 7. CONCLUSIONS The importance of research in the fields of glucose homeostasis, insulin and diabetes has not faded. In fact, due to rapid globalization and the normalization of a sedentary lifestyle, along with increased obesity, diabetes and their consequent co-morbidities, research in this topic must continue to grow. Understanding the mechanisms implicated in every step in the development and complications of T2DM is crucial in order to prevent, control, treat or revert the pathophysiology of T2DM its complications. Although quality outcomes for patients are optimized by early detection of T2DM through screening and intensive patient-centered management, research efforts are needed to define causative factors accounting for correlations among different demographic subsets and the corresponding variable risks for T2DM as well as the drivers of increased risk in individuals of low socioeconomic status. Being the pathophysiology and underlying mechanisms of T2DM increasingly understood, precision medicine should be implemented and treatments individualized and targeted appropriately with the help of molecular genetic tools by identifying specific variants contributing to disease development as well as by searching biomarkers to assess progression and response to therapeutic interventions. Additional research is needed to determine a direct causal role of the intestinal microbiota in pathogenesis of T2DM and response to therapies needs to be determined. Taking everything in this review into consideration, it is clear that there is still a long way until we fully understand each of the many stakeholders in glucose homeostasis. REFERENCES [1.] Roden M. Shulman G.I. The integrative biology of type 2 diabetes Nature 2019 576 51 60 10.1038/s41586-019-1797-8 31802013 [2.] Stumvoll M. Goldstein B.J. van Haeften T.W. Type 2 diabetes: Principles of pathogenesis and therapy Lancet 2005 365 1333 1346 10.1016/S0140-6736(05)61032-X 15823385 [3.] Weyer C. Bogardus C. Mott D.M. Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J. Clin. Investig. 1999 104 787 794 10.1172/JCI7231 10491414 PMC408438 [4.] Chatterjee S. Khunti K. Davies M.J. Type 2 diabetes Lancet 2017 389 2239 2251 10.1016/S0140-6736(17)30058-2 28190580 [5.] NCD Risk Factor Collaboration Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants Lancet 2016 387 1513 1530 10.1016/S0140-6736(16)00618-8 27061677 PMC5081106 [6.] Defronzo R.A. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773 795 10.2337/db09-9028 19336687 PMC2661582 [7.] Schwartz S.S. Epstein S. Corkey B.E. Grant S.F. Gavin J.R. 3rd Aguilar R.B. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the beta-Cell-Centric Classification Schema Diabetes Care 2016 39 179 186 10.2337/dc15-1585 26798148 PMC5317235 [8.] Gaede P. Vedel P. Larsen N. Jensen G.V. Parving H.H. Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N. Engl. J. Med. 2003 348 383 393 10.1056/NEJMoa021778 12556541 [9.] Sarwar N. Gao P. Seshasai S.R. Gobin R. Kaptoge S. Di Angelantonio E. Ingelsson E. Lawlor D.A. Selvin E. Stampfer M. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies Lancet 2010 375 2215 2222 10.1016/S0140-6736(10)60484-9 20609967 PMC2904878 [10.] Grarup N. Sandholt C.H. Hansen T. Pedersen O. Genetic susceptibility to type 2 diabetes and obesity: From genome-wide association studies to rare variants and beyond Diabetologia 2014 57 1528 1541 10.1007/s00125-014-3270-4 24859358 [11.] Wong N.D. Zhao Y. Patel R. Patao C. Malik S. Bertoni A.G. Correa A. Folsom A.R. Kachroo S. Mukherjee J. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study Diabetes Care 2016 39 668 676 10.2337/dc15-2439 27208374 PMC4839178 [12.] Hu F.B. Manson J.E. Stampfer M.J. Colditz G. Liu S. Solomon C.G. Willett W.C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women N. Engl. J. Med. 2001 345 790 797 10.1056/NEJMoa010492 11556298 [13.] Schellenberg E.S. Dryden D.M. Vandermeer B. Ha C. Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: A systematic review and meta-analysis Ann. Intern. Med. 2013 159 543 551 10.7326/0003-4819-159-8-201310150-00007 24126648 [14.] Chan J.C. Cheung C.K. Swaminathan R. Nicholls M.G. Cockram C.S. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM) Postgrad. Med. J. 1993 69 204 210 10.1136/pgmj.69.809.204 8497435 PMC2399753 [15.] Dabelea D. DeGroat J. Sorrelman C. Glass M. Percy C.A. Avery C. Hu D. D’Agostino R.B. Jr. Beyer J. Imperatore G. Search for Diabetes in Navajo youth: Prevalence, incidence, and clinical characteristics: The Search for Diabetes in Youth Study Diabetes Care 2009 32 Suppl. 2 S141 S147 10.2337/dc09-S206 19246579 PMC2647690 [16.] Liu L.L. Yi J.P. Beyer J. Mayer-Davis E.J. Dolan L.M. Dabelea D.M. Lawrence J.M. Rodriguez B.L. Marcovina S.M. Waitzfelder B.E. Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: The SEARCH for Diabetes in Youth Study Diabetes Care 2009 32 Suppl. 2 S133 S140 10.2337/dc09-S205 19246578 PMC2647693 [17.] Karter A.J. Schillinger D. Adams A.S. Moffet H.H. Liu J. Adler N.E. Kanaya A.M. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: The Diabetes Study of Northern California (DISTANCE) Diabetes Care 2013 36 574 579 10.2337/dc12-0722 23069837 PMC3579366 [18.] Sattar N. Gill J.M. Type 2 diabetes in migrant south Asians: Mechanisms, mitigation, and management Lancet Diabetes Endocrinol. 2015 3 1004 1016 10.1016/S2213-8587(15)00326-5 26489808 [19.] McKeigue P.M. Shah B. Marmot M.G. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians Lancet 1991 337 382 386 10.1016/0140-6736(91)91164-P 1671422 [20.] Haines L. Wan K.C. Lynn R. Barrett T.G. Shield J.P. Rising incidence of type 2 diabetes in children in the U.K Diabetes Care 2007 30 1097 1101 10.2337/dc06-1813 17259470 [21.] Fuchsberger C. Flannick J. Teslovich T.M. Mahajan A. Agarwala V. Gaulton K.J. Ma C. Fontanillas P. Moutsianas L. McCarthy D.J. The genetic architecture of type 2 diabetes Nature 2016 536 41 47 10.1038/nature18642 27398621 PMC5034897 [22.] McCarthy M.I. Genomics, type 2 diabetes, and obesity N. Engl. J. Med. 2010 363 2339 2350 10.1056/NEJMra0906948 21142536 [23.] Dimas A.S. Lagou V. Barker A. Knowles J.W. Magi R. Hivert M.F. Benazzo A. Rybin D. Jackson A.U. Stringham H.M. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity Diabetes 2014 63 2158 2171 10.2337/db13-0949 24296717 PMC4030103 [24.] Flannick J. Florez J.C. Type 2 diabetes: Genetic data sharing to advance complex disease research Nat. Rev. Genet. 2016 17 535 549 10.1038/nrg.2016.56 27402621 [25.] Franks P.W. Pearson E. Florez J.C. Gene-environment and gene-treatment interactions in type 2 diabetes: Progress, pitfalls, and prospects Diabetes Care 2013 36 1413 1421 10.2337/dc12-2211 23613601 PMC3631878 [26.] Bellou V. Belbasis L. Tzoulaki I. Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses PLoS ONE 2018 13 e0194127 10.1371/journal.pone.0194127 29558518 PMC5860745 [27.] Carey V.J. Walters E.E. Colditz G.A. Solomon C.G. Willett W.C. Rosner B.A. Speizer F.E. Manson J.E. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study Am. J. Epidemiol. 1997 145 614 619 10.1093/oxfordjournals.aje.a009158 9098178 [28.] Sinha R. Dufour S. Petersen K.F. LeBon V. Enoksson S. Ma Y.Z. Savoye M. Rothman D.L. Shulman G.I. Caprio S. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: Relationships to insulin sensitivity, total body fat, and central adiposity Diabetes 2002 51 1022 1027 10.2337/diabetes.51.4.1022 11916921 [29.] Hillier T.A. Pedula K.L. Complications in young adults with early-onset type 2 diabetes: Losing the relative protection of youth Diabetes Care 2003 26 2999 3005 10.2337/diacare.26.11.2999 14578230 [30.] Weinstein A.R. Sesso H.D. Lee I.M. Cook N.R. Manson J.E. Buring J.E. Gaziano J.M. Relationship of physical activity vs body mass index with type 2 diabetes in women JAMA 2004 292 1188 1194 10.1001/jama.292.10.1188 15353531 [31.] Lynch J. Helmrich S.P. Lakka T.A. Kaplan G.A. Cohen R.D. Salonen R. Salonen J.T. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men Arch. Intern. Med. 1996 156 1307 1314 10.1001/archinte.1996.00440110073010 8651839 [32.] Venkatasamy V.V. Pericherla S. Manthuruthil S. Mishra S. Hanno R. Effect of Physical activity on Insulin Resistance, Inflammation and Oxidative Stress in Diabetes Mellitus J. Clin. Diagn. Res. 2013 7 1764 1766 10.7860/JCDR/2013/6518.3306 24086908 PMC3782965 [33.] Strasser B. Physical activity in obesity and metabolic syndrome Ann. N. Y. Acad. Sci. 2013 1281 141 159 10.1111/j.1749-6632.2012.06785.x 23167451 PMC3715111 [34.] Ross R. Does exercise without weight loss improve insulin sensitivity? Diabetes Care 2003 26 944 945 10.2337/diacare.26.3.944 12610063 [35.] Cerf M.E. Beta cell dysfunction and insulin resistance Front. Endocrinol. (Lausanne) 2013 4 37 10.3389/fendo.2013.00037 23542897 PMC3608918 [36.] Zheng Y. Ley S.H. Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications Nat. Rev. Endocrinol. 2018 14 88 98 10.1038/nrendo.2017.151 29219149 [37.] Bunney P.E. Zink A.N. Holm A.A. Billington C.J. Kotz C.M. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet Physiol. Behav. 2017 176 139 148 10.1016/j.physbeh.2017.03.040 28363838 PMC5510739 [38.] Fu Z. Gilbert E.R. Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes Curr. Diabetes Rev. 2013 9 25 53 10.2174/157339913804143225 22974359 PMC3934755 [39.] Halban P.A. Proinsulin processing in the regulated and the constitutive secretory pathway Diabetologia 1994 37 Suppl. 2 S65 S72 10.1007/BF00400828 7821742 [40.] Boland B.B. Rhodes C.J. Grimsby J.S. The dynamic plasticity of insulin production in beta-cells Mol. Metab. 2017 6 958 973 10.1016/j.molmet.2017.04.010 28951821 PMC5605729 [41.] Rorsman P. Ashcroft F.M. Pancreatic beta-Cell Electrical Activity and Insulin Secretion: Of Mice and Men Physiol. Rev. 2018 98 117 214 10.1152/physrev.00008.2017 29212789 PMC5866358 [42.] Seino S. Shibasaki T. Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes J. Clin. Investig. 2011 121 2118 2125 10.1172/JCI45680 21633180 PMC3104758 [43.] Islam M.S. The ryanodine receptor calcium channel of beta-cells: Molecular regulation and physiological significance Diabetes 2002 51 1299 1309 10.2337/diabetes.51.5.1299 11978625 [44.] Cuinas A. Garcia-Morales V. Vina D. Gil-Longo J. Campos-Toimil M. Activation of PKA and Epac proteins by cyclic AMP depletes intracellular calcium stores and reduces calcium availability for vasoconstriction Life Sci. 2016 155 102 109 10.1016/j.lfs.2016.03.059 27142830 [45.] Lustig K.D. Shiau A.K. Brake A.J. Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells Proc. Natl. Acad. Sci. USA 1993 90 5113 5117 10.1073/pnas.90.11.5113 7685114 PMC46665 [46.] Simon J. Webb T.E. King B.F. Burnstock G. Barnard E.A. Characterisation of a recombinant P2Y purinoceptor Eur. J. Pharmacol. 1995 291 281 289 10.1016/0922-4106(95)90068-3 8719412 [47.] Valera S. Hussy N. Evans R.J. Adami N. North R.A. Surprenant A. Buell G. A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP Nature 1994 371 516 519 10.1038/371516a0 7523951 [48.] Blachier F. Malaisse W.J. Effect of exogenous ATP upon inositol phosphate production, cationic fluxes and insulin release in pancreatic islet cells Biochim. Biophys. Acta 1988 970 222 229 10.1016/0167-4889(88)90182-6 2454675 [49.] Li G.D. Milani D. Dunne M.J. Pralong W.F. Theler J.M. Petersen O.H. Wollheim C.B. Extracellular ATP causes Ca 2(+)− dependent and -independent insulin secretion in RINm5F cells. Phospholipase C mediates Ca 2+ mobilization but not Ca 2+ influx and membrane depolarization J. Biol. Chem. 1991 266 3449 3457 1995609 [50.] Christensen A.A. Gannon M. The Beta Cell in Type 2 Diabetes Curr. Diabetes Rep. 2019 19 81 10.1007/s11892-019-1196-4 31399863 [51.] Halban P.A. Polonsky K.S. Bowden D.W. Hawkins M.A. Ling C. Mather K.J. Powers A.C. Rhodes C.J. Sussel L. Weir G.C. beta-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment Diabetes Care 2014 37 1751 1758 10.2337/dc14-0396 24812433 PMC4179518 [52.] Yamamoto W.R. Bone R.N. Sohn P. Syed F. Reissaus C.A. Mosley A.L. Wijeratne A.B. True J.D. Tong X. Kono T. Endoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic beta cell J. Biol. Chem. 2019 294 168 181 10.1074/jbc.RA118.005683 30420428 PMC6322901 [53.] Hoang Do O. Thorn P. Insulin secretion from beta cells within intact islets: Location matters Clin. Exp. Pharmacol. Physiol. 2015 42 406 414 10.1111/1440-1681.12368 25676261 PMC4418378 [54.] Liu M. Weiss M.A. Arunagiri A. Yong J. Rege N. Sun J. Haataja L. Kaufman R.J. Arvan P. Biosynthesis, structure, and folding of the insulin precursor protein Diabetes Obes. Metab. 2018 20 Suppl. 2 28 50 10.1111/dom.13378 30230185 PMC6463291 [55.] Dali-Youcef N. Mecili M. Ricci R. Andres E. Metabolic inflammation: Connecting obesity and insulin resistance Ann. Med. 2013 45 242 253 10.3109/07853890.2012.705015 22834949 [56.] Hummasti S. Hotamisligil G.S. Endoplasmic reticulum stress and inflammation in obesity and diabetes Circ. Res. 2010 107 579 591 10.1161/CIRCRESAHA.110.225698 20814028 [57.] Roca-Rivada A. Castelao C. Senin L.L. Landrove M.O. Baltar J. Belen Crujeiras A. Seoane L.M. Casanueva F.F. Pardo M. FNDC5/irisin is not only a myokine but also an adipokine PLoS ONE 2013 8 e60563 10.1371/journal.pone.0060563 23593248 PMC3623960 [58.] Giacco F. Brownlee M. Oxidative stress and diabetic complications Circ. Res. 2010 107 1058 1070 10.1161/CIRCRESAHA.110.223545 21030723 PMC2996922 [59.] Graciano M.F. Valle M.M. Kowluru A. Curi R. Carpinelli A.R. Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets Islets 2011 3 213 223 10.4161/isl.3.5.15935 21750413 [60.] Esser N. Legrand-Poels S. Piette J. Scheen A.J. Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes Diabetes Res. Clin. Pract. 2014 105 141 150 10.1016/j.diabres.2014.04.006 24798950 [61.] Pradhan A.D. Manson J.E. Rifai N. Buring J.E. Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 2001 286 327 334 10.1001/jama.286.3.327 11466099 [62.] Vandanmagsar B. Youm Y.H. Ravussin A. Galgani J.E. Stadler K. Mynatt R.L. Ravussin E. Stephens J.M. Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance Nat. Med. 2011 17 179 188 10.1038/nm.2279 21217695 PMC3076025 [63.] Association A.D. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019 Diabetes Care 2019 42 S29 S33 10.2337/dc19-S003 30559229 [64.] Shamsuzzaman A.S. Winnicki M. Wolk R. Svatikova A. Phillips B.G. Davison D.E. Berger P.B. Somers V.K. Independent association between plasma leptin and C-reactive protein in healthy humans Circulation 2004 109 2181 2185 10.1161/01.CIR.0000127960.28627.75 15117839 [65.] Leeuwenburgh C. Fiebig R. Chandwaney R. Ji L.L. Aging and exercise training in skeletal muscle: Responses of glutathione and antioxidant enzyme systems Am. J. Physiol. 1994 267 R439 R445 10.1152/ajpregu.1994.267.2.R439 8067452 [66.] Polak K. Czyzyk A. Simoncini T. Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome J. Endocrinol. Investig. 2017 40 1 8 10.1007/s40618-016-0523-8 27473078 PMC5206255 [67.] Bostrom P. Wu J. Jedrychowski M.P. Korde A. Ye L. Lo J.C. Rasbach K.A. Bostrom E.A. Choi J.H. Long J.Z. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis Nature 2012 481 463 468 10.1038/nature10777 22237023 PMC3522098 [68.] Handschin C. Spiegelman B.M. The role of exercise and PGC1alpha in inflammation and chronic disease Nature 2008 454 463 469 10.1038/nature07206 18650917 PMC2587487 [69.] Park K.H. Zaichenko L. Brinkoetter M. Thakkar B. Sahin-Efe A. Joung K.E. Tsoukas M.A. Geladari E.V. Huh J.Y. Dincer F. Circulating irisin in relation to insulin resistance and the metabolic syndrome J. Clin. Endocrinol. Metab. 2013 98 4899 4907 10.1210/jc.2013-2373 24057291 PMC3849667 [70.] El-Lebedy D.H. Ibrahim A.A. Ashmawy I.O. Novel adipokines vaspin and irisin as risk biomarkers for cardiovascular diseases in type 2 diabetes mellitus Diabetes Metab. Syndr. 2018 12 643 648 10.1016/j.dsx.2018.04.025 29673927 [71.] Lynch S.V. Pedersen O. The Human Intestinal Microbiome in Health and Disease N. Engl. J. Med. 2016 375 2369 2379 10.1056/NEJMra1600266 27974040 [72.] Ochoa-Reparaz J. Kasper L.H. Gut microbiome and the risk factors in central nervous system autoimmunity FEBS Lett. 2014 588 4214 4222 10.1016/j.febslet.2014.09.024 25286403 PMC4254300 [73.] Scarpellini E. Tack J. Obesity and metabolic syndrome: An inflammatory condition Dig. Dis. 2012 30 148 153 10.1159/000336664 22722429 [74.] Biagi E. Candela M. Fairweather-Tait S. Franceschi C. Brigidi P. Aging of the human metaorganism: The microbial counterpart Age (Dordrecht) 2012 34 247 267 10.1007/s11357-011-9217-5 PMC3260362 21347607 [75.] Sircana A. Framarin L. Leone N. Berrutti M. Castellino F. Parente R. De Michieli F. Paschetta E. Musso G. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? Curr. Diabetes Rep. 2018 18 98 10.1007/s11892-018-1057-6 30215149 [76.] Li X. Watanabe K. Kimura I. Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases Front. Immunol. 2017 8 1882 10.3389/fimmu.2017.01882 29326727 PMC5742320 [77.] Cani P.D. Amar J. Iglesias M.A. Poggi M. Knauf C. Bastelica D. Neyrinck A.M. Fava F. Tuohy K.M. Chabo C. Metabolic endotoxemia initiates obesity and insulin resistance Diabetes 2007 56 1761 1772 10.2337/db06-1491 17456850 [78.] Tan J. McKenzie C. Potamitis M. Thorburn A.N. Mackay C.R. Macia L. The role of short-chain fatty acids in health and disease Adv. Immunol. 2014 121 91 119 10.1016/B978-0-12-800100-4.00003-9 24388214 [79.] Tang C. Ahmed K. Gille A. Lu S. Grone H.J. Tunaru S. Offermanns S. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes Nat. Med. 2015 21 173 177 10.1038/nm.3779 25581519 [80.] Neis E.P. Dejong C.H. Rensen S.S. The role of microbial amino acid metabolism in host metabolism Nutrients 2015 7 2930 2946 10.3390/nu7042930 25894657 PMC4425181 [81.] Shan Z. Sun T. Huang H. Chen S. Chen L. Luo C. Yang W. Yang X. Yao P. Cheng J. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes Am. J. Clin. Nutr. 2017 106 888 894 10.3945/ajcn.117.157107 28724646 [82.] Turner R.C. Cull C.A. Frighi V. Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 1999 281 2005 2012 10.1001/jama.281.21.2005 10359389 [83.] Gaede P.H. Jepsen P.V. Larsen J.N. Jensen G.V. Parving H.H. Pedersen O.B. The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes Ugeskr. Laeger. 2003 165 2658 2661 12886549 [84.] Holman R.R. Paul S.K. Bethel M.A. Matthews D.R. Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes N. Engl. J. Med. 2008 359 1577 1589 10.1056/NEJMoa0806470 18784090 [85.] Ihnat M.A. Thorpe J.E. Kamat C.D. Szabo C. Green D.E. Warnke L.A. Lacza Z. Cselenyak A. Ross K. Shakir S. Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling Diabetologia 2007 50 1523 1531 10.1007/s00125-007-0684-2 17508197 [86.] Ceriello A. Ihnat M.A. Thorpe J.E. Clinical review 2: The “metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab. 2009 94 410 415 10.1210/jc.2008-1824 19066300 [87.] Engerman R.L. Pathogenesis of diabetic retinopathy Diabetes 1989 38 1203 1206 10.2337/diab.38.10.1203 2676655 [88.] Olsen A.S. Sarras M.P. Jr. Leontovich A. Intine R.V. Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression Diabetes 2012 61 485 491 10.2337/db11-0588 22228713 PMC3266410 [89.] Simmons D. Epigenetic Influences and Disease Nat. Educ. 2008 1 6 [90.] Rosen E.D. Kaestner K.H. Natarajan R. Patti M.E. Sallari R. Sander M. Susztak K. Epigenetics and Epigenomics: Implications for Diabetes and Obesity Diabetes 2018 67 1923 1931 10.2337/db18-0537 30237160 PMC6463748 [91.] Wahid F. Shehzad A. Khan T. Kim Y.Y. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials Biochim. Biophys. Acta 2010 1803 1231 1243 10.1016/j.bbamcr.2010.06.013 20619301 [92.] LaPierre M.P. Stoffel M. MicroRNAs as stress regulators in pancreatic beta cells and diabetes Mol. Metab. 2017 6 1010 1023 10.1016/j.molmet.2017.06.020 28951825 PMC5605735 [93.] Esguerra J.L.S. Nagao M. Ofori J.K. Wendt A. Eliasson L. MicroRNAs in islet hormone secretion Diabetes Obes. Metab. 2018 20 Suppl. 2 11 19 10.1111/dom.13382 30230181 [94.] Ofori J.K. Salunkhe V.A. Bagge A. Vishnu N. Nagao M. Mulder H. Wollheim C.B. Eliasson L. Esguerra J.L. Elevated miR-130a/miR130b/miR-152 expression reduces intracellular ATP levels in the pancreatic beta cell Sci. Rep. 2017 7 44986 10.1038/srep44986 28332581 PMC5362944 [95.] Latreille M. Hausser J. Stutzer I. Zhang Q. Hastoy B. Gargani S. Kerr-Conte J. Pattou F. Zavolan M. Esguerra J.L. MicroRNA-7a regulates pancreatic beta cell function J. Clin. Investig. 2014 124 2722 2735 10.1172/JCI73066 24789908 PMC4038573 [96.] Poy M.N. Hausser J. Trajkovski M. Braun M. Collins S. Rorsman P. Zavolan M. Stoffel M. miR-375 maintains normal pancreatic alpha- and beta-cell mass Proc. Natl. Acad. Sci. USA 2009 106 5813 5818 10.1073/pnas.0810550106 19289822 PMC2656556 [97.] Latreille M. Herrmanns K. Renwick N. Tuschl T. Malecki M.T. McCarthy M.I. Owen K.R. Rulicke T. Stoffel M. miR-375 gene dosage in pancreatic beta-cells: Implications for regulation of beta-cell mass and biomarker development J. Mol. Med. (Berl.) 2015 93 1159 1169 10.1007/s00109-015-1296-9 26013143 PMC4589563 [98.] Reddy M.A. Zhang E. Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory Diabetologia 2015 58 443 455 10.1007/s00125-014-3462-y 25481708 PMC4324095 [99.] Blomen V.A. Boonstra J. Stable transmission of reversible modifications: Maintenance of epigenetic information through the cell cycle Cell. Mol. Life Sci. 2011 68 27 44 10.1007/s00018-010-0505-5 20799050 PMC3015210 [100.] Bogdanovic O. Veenstra G.J. DNA methylation and methyl-CpG binding proteins: Developmental requirements and function Chromosoma 2009 118 549 565 10.1007/s00412-009-0221-9 19506892 PMC2729420 [101.] Mosammaparast N. Shi Y. Reversal of histone methylation: Biochemical and molecular mechanisms of histone demethylases Annu. Rev. Biochem. 2010 79 155 179 10.1146/annurev.biochem.78.070907.103946 20373914 [102.] Breving K. Esquela-Kerscher A. The complexities of microRNA regulation: Mirandering around the rules Int. J. Biochem. Cell. Biol. 2010 42 1316 1329 10.1016/j.biocel.2009.09.016 19800023 [103.] Brasacchio D. Okabe J. Tikellis C. Balcerczyk A. George P. Baker E.K. Calkin A.C. Brownlee M. Cooper M.E. El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail Diabetes 2009 58 1229 1236 10.2337/db08-1666 19208907 PMC2671038 [104.] Miao F. Gonzalo I.G. Lanting L. Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions J. Biol. Chem. 2004 279 18091 18097 10.1074/jbc.M311786200 14976218 [105.] Reddy M.A. Natarajan R. Epigenetic mechanisms in diabetic vascular complications Cardiovasc. Res. 2011 90 421 429 10.1093/cvr/cvr024 21266525 PMC3096305 [106.] Al-Haddad R. Karnib N. Assaad R.A. Bilen Y. Emmanuel N. Ghanem A. Younes J. Zibara V. Stephan J.S. Sleiman S.F. Epigenetic changes in diabetes Neurosci. Lett. 2016 625 64 69 10.1016/j.neulet.2016.04.046 27130819 [107.] Nishikawa T. Edelstein D. Du X.L. Yamagishi S. Matsumura T. Kaneda Y. Yorek M.A. Beebe D. Oates P.J. Hammes H.P. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 2000 404 787 790 10.1038/35008121 10783895 [108.] Kowluru R.A. Kanwar M. Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries Exp. Diabetes Res. 2007 2007 21976 10.1155/2007/21976 17641740 PMC1906703 [109.] Kowluru R.A. Abbas S.N. Odenbach S. Reversal of hyperglycemia and diabetic nephropathy: Effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats J. Diabetes Complicat. 2004 18 282 288 10.1016/j.jdiacomp.2004.03.002 15337502 [110.] Thompson J.A. Webb R.C. Potential role of Toll-like receptors in programming of vascular dysfunction Clin. Sci. (Lond.) 2013 125 19 25 10.1042/CS20120673 23485061 PMC4004342 [111.] Guarner V. Rubio-Ruiz M.E. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease Interdiscip. Top Gerontol. 2015 40 99 106 10.1159/000364934 25341516 [112.] Kim J.A. Wei Y. Sowers J.R. Role of mitochondrial dysfunction in insulin resistance Circ. Res. 2008 102 401 414 10.1161/CIRCRESAHA.107.165472 18309108 PMC2963150 [113.] Stump C.S. Short K.R. Bigelow M.L. Schimke J.M. Nair K.S. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts Proc. Natl. Acad. Sci. USA 2003 100 7996 8001 10.1073/pnas.1332551100 12808136 PMC164701 [114.] Petersen K.F. Befroy D. Dufour S. Dziura J. Ariyan C. Rothman D.L. DiPietro L. Cline G.W. Shulman G.I. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance Science 2003 300 1140 1142 10.1126/science.1082889 12750520 PMC3004429 [115.] Sazanov L.A. A giant molecular proton pump: Structure and mechanism of respiratory complex I Nat. Rev. Mol. Cell. Biol. 2015 16 375 388 10.1038/nrm3997 25991374 [116.] Anonymous Focusing on mitochondrial form and function Nat. Cell. Biol. 2018 20 735 10.1038/s41556-018-0139-7 29950569 [117.] Spinelli J.B. Haigis M.C. The multifaceted contributions of mitochondria to cellular metabolism Nat. Cell. Biol. 2018 20 745 754 10.1038/s41556-018-0124-1 29950572 PMC6541229 [118.] Shigenaga M.K. Hagen T.M. Ames B.N. Oxidative damage and mitochondrial decay in aging Proc. Natl. Acad. Sci. USA 1994 91 10771 10778 10.1073/pnas.91.23.10771 7971961 PMC45108 [119.] Sergi D. Naumovski N. Heilbronn L.K. Abeywardena M. O’Callaghan N. Lionetti L. Luscombe-Marsh N. Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet Front. Physiol. 2019 10 532 10.3389/fphys.2019.00532 31130874 PMC6510277 [120.] Kelley D.E. Goodpaster B. Wing R.R. Simoneau J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss Am. J. Physiol. 1999 277 E1130 E1141 10.1152/ajpendo.1999.277.6.E1130 10600804 [121.] Simoneau J.A. Veerkamp J.H. Turcotte L.P. Kelley D.E. Markers of capacity to utilize fatty acids in human skeletal muscle: Relation to insulin resistance and obesity and effects of weight loss FASEB J. 1999 13 2051 2060 10.1096/fasebj.13.14.2051 10544188 [122.] Kim J.Y. Hickner R.C. Cortright R.L. Dohm G.L. Houmard J.A. Lipid oxidation is reduced in obese human skeletal muscle Am. J. Physiol. Endocrinol. Metab. 2000 279 E1039 E1044 10.1152/ajpendo.2000.279.5.E1039 11052958 [123.] Mootha V.K. Lindgren C.M. Eriksson K.F. Subramanian A. Sihag S. Lehar J. Puigserver P. Carlsson E. Ridderstrale M. Laurila E. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes Nat. Genet. 2003 34 267 273 10.1038/ng1180 12808457 [124.] Patti M.E. Butte A.J. Crunkhorn S. Cusi K. Berria R. Kashyap S. Miyazaki Y. Kohane I. Costello M. Saccone R. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 Proc. Natl. Acad. Sci. USA 2003 100 8466 8471 10.1073/pnas.1032913100 12832613 PMC166252 [125.] Schrauwen-Hinderling V.B. Kooi M.E. Hesselink M.K. Jeneson J.A. Backes W.H. van Echteld C.J. van Engelshoven J.M. Mensink M. Schrauwen P. Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects Diabetologia 2007 50 113 120 10.1007/s00125-006-0475-1 17093944 [126.] Phielix E. Schrauwen-Hinderling V.B. Mensink M. Lenaers E. Meex R. Hoeks J. Kooi M.E. Moonen-Kornips E. Sels J.P. Hesselink M.K. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients Diabetes 2008 57 2943 2949 10.2337/db08-0391 18678616 PMC2570390 [127.] Schieber M. Chandel N.S. ROS function in redox signaling and oxidative stress Curr. Biol. 2014 24 R453 R462 10.1016/j.cub.2014.03.034 24845678 PMC4055301 [128.] Ezraty B. Gennaris A. Barras F. Collet J.F. Oxidative stress, protein damage and repair in bacteria Nat. Rev. Microbiol. 2017 15 385 396 10.1038/nrmicro.2017.26 28420885 [129.] Ceriello A. The emerging challenge in diabetes: The “metabolic memory” Vascul. Pharmacol. 2012 57 133 138 10.1016/j.vph.2012.05.005 22609133 [130.] Johnson A.R. Milner J.J. Makowski L. The inflammation highway: Metabolism accelerates inflammatory traffic in obesity Immunol. Rev. 2012 249 218 238 10.1111/j.1600-065X.2012.01151.x 22889225 PMC3422768 [131.] Schofield J.H. Schafer Z.T. Mitochondrial Reactive Oxygen Species and Mitophagy: A Complex and Nuanced Relationship Antioxid. Redox. Signal 2020 10.1089/ars.2020.8058 32079408 [132.] Montgomery M.K. Turner N. Mitochondrial dysfunction and insulin resistance: An update Endocr. Connect. 2015 4 R1 R15 10.1530/EC-14-0092 25385852 PMC4261703 [133.] Chavez J.A. Summers S.A. A ceramide-centric view of insulin resistance Cell. Metab. 2012 15 585 594 10.1016/j.cmet.2012.04.002 22560211 [134.] Liang H. Ward W.F. PGC-1alpha: A key regulator of energy metabolism Adv. Physiol. Educ. 2006 30 145 151 10.1152/advan.00052.2006 17108241 [135.] Bach D. Naon D. Pich S. Soriano F.X. Vega N. Rieusset J. Laville M. Guillet C. Boirie Y. Wallberg-Henriksson H. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6 Diabetes 2005 54 2685 2693 10.2337/diabetes.54.9.2685 16123358 [136.] Novak I. Mitophagy: A complex mechanism of mitochondrial removal Antioxid. Redox. Signal 2012 17 794 802 10.1089/ars.2011.4407 22077334 [137.] Wei H. Liu L. Chen Q. Selective removal of mitochondria via mitophagy: Distinct pathways for different mitochondrial stresses Biochim. Biophys. Acta 2015 1853 2784 2790 10.1016/j.bbamcr.2015.03.013 25840011 [138.] Ding W.X. Yin X.M. Mitophagy: Mechanisms, pathophysiological roles, and analysis Biol. Chem. 2012 393 547 564 10.1515/hsz-2012-0119 22944659 PMC3630798 [139.] Westermann B. Mitochondrial fusion and fission in cell life and death Nat. Rev. Mol. Cell. Biol. 2010 11 872 884 10.1038/nrm3013 21102612 [140.] Yang L. Li P. Fu S. Calay E.S. Hotamisligil G.S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance Cell. Metab. 2010 11 467 478 10.1016/j.cmet.2010.04.005 20519119 PMC2881480 [141.] Quiros P.M. Ramsay A.J. Sala D. Fernandez-Vizarra E. Rodriguez F. Peinado J.R. Fernandez-Garcia M.S. Vega J.A. Enriquez J.A. Zorzano A. Loss of mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes obesity and defective thermogenesis in mice EMBO J. 2012 31 2117 2133 10.1038/emboj.2012.70 22433842 PMC3343468 [142.] Sebastian D. Hernandez-Alvarez M.I. Segales J. Sorianello E. Munoz J.P. Sala D. Waget A. Liesa M. Paz J.C. Gopalacharyulu P. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis Proc. Natl. Acad. Sci. USA 2012 109 5523 5528 10.1073/pnas.1108220109 22427360 PMC3325712 [143.] Jheng H.F. Tsai P.J. Guo S.M. Kuo L.H. Chang C.S. Su I.J. Chang C.R. Tsai Y.S. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle Mol. Cell. Biol. 2012 32 309 319 10.1128/MCB.05603-11 22083962 PMC3255771 [144.] Lin H.Y. Weng S.W. Chang Y.H. Su Y.J. Chang C.M. Tsai C.J. Shen F.C. Chuang J.H. Lin T.K. Liou C.W. The Causal Role of Mitochondrial Dynamics in Regulating Insulin Resistance in Diabetes: Link through Mitochondrial Reactive Oxygen Species Oxid. Med. Cell. Longev. 2018 2018 7514383 10.1155/2018/7514383 30363990 PMC6186363 [145.] Lionetti L. Mollica M.P. Donizzetti I. Gifuni G. Sica R. Pignalosa A. Cavaliere G. Gaita M. De Filippo C. Zorzano A. High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria PLoS ONE 2014 9 e92753 10.1371/journal.pone.0092753 24663492 PMC3963938 [146.] Kadowaki T. Kadowaki H. Mori Y. Tobe K. Sakuta R. Suzuki Y. Tanabe Y. Sakura H. Awata T. Goto Y. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA N. Engl. J. Med. 1994 330 962 968 10.1056/NEJM199404073301403 8121460 [147.] Yang B.T. Dayeh T.A. Volkov P.A. Kirkpatrick C.L. Malmgren S. Jing X. Renstrom E. Wollheim C.B. Nitert M.D. Ling C. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes Mol. Endocrinol. 2012 26 1203 1212 10.1210/me.2012-1004 22570331 PMC5416998 [148.] Tawata M. Hayashi J.I. Isobe K. Ohkubo E. Ohtaka M. Chen J. Aida K. Onaya T. A new mitochondrial DNA mutation at 14577 T/C is probably a major pathogenic mutation for maternally inherited type 2 diabetes Diabetes 2000 49 1269 1272 10.2337/diabetes.49.7.1269 10909988 [149.] Wang D. Taniyama M. Suzuki Y. Katagiri T. Ban Y. Association of the mitochondrial DNA 5178A/C polymorphism with maternal inheritance and onset of type 2 diabetes in Japanese patients Exp. Clin. Endocrinol. Diabetes 2001 109 361 364 10.1055/s-2001-17407 11573146 [150.] Tawata M. Ohtaka M. Iwase E. Ikegishi Y. Aida K. Onaya T. New mitochondrial DNA homoplasmic mutations associated with Japanese patients with type 2 diabetes Diabetes 1998 47 276 277 10.2337/diab.47.2.276 9519725 [151.] Poulton J. Luan J. Macaulay V. Hennings S. Mitchell J. Wareham N.J. Type 2 diabetes is associated with a common mitochondrial variant: Evidence from a population-based case-control study Hum. Mol. Genet. 2002 11 1581 1583 10.1093/hmg/11.13.1581 12045211 [152.] Tang D.L. Zhou X. Li X. Zhao L. Liu F. Variation of mitochondrial gene and the association with type 2 diabetes mellitus in a Chinese population Diabetes Res. Clin. Pract. 2006 73 77 82 10.1016/j.diabres.2005.12.001 16414144 [153.] Czech M.P. Insulin action and resistance in obesity and type 2 diabetes Nat. Med. 2017 23 804 814 10.1038/nm.4350 28697184 PMC6048953 [154.] Pearson T. Wattis J.A. King J.R. MacDonald I.A. Mazzatti D.J. The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans Bull. Math. Biol. 2016 78 1189 1217 10.1007/s11538-016-0181-1 27306890 PMC4949305 [155.] Wilcox G. Insulin and insulin resistance Clin. Biochem. Rev. 2005 26 19 39 16278749 PMC1204764 [156.] Nussey S. Whitehead S. Endocrinology: An Integrated Approach BIOS Scientific Publishers Oxford, UK 2001 20821847 [157.] Petersen K.F. Shulman G.I. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus Am. J. Cardiol. 2002 90 11G 18G 10.1016/S0002-9149(02)02554-7 12231074 [158.] Petersen K.F. Shulman G.I. Cellular mechanism of insulin resistance in skeletal muscle J. R Soc. Med. 2002 95 Suppl. 42 8 13 12216329 PMC1308947 [159.] Satoh T. Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes Int. J. Mol. Sci. 2014 15 18677 18692 10.3390/ijms151018677 25325535 PMC4227239 [160.] DeFronzo R.A. Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes 1988 37 667 687 10.2337/diab.37.6.667 3289989 [161.] Abdul-Ghani M.A. DeFronzo R.A. Pathogenesis of insulin resistance in skeletal muscle J. Biomed. Biotechnol. 2010 2010 476279 10.1155/2010/476279 20445742 PMC2860140 [162.] Wu H. Ballantyne C.M. Skeletal muscle inflammation and insulin resistance in obesity J. Clin. Investig. 2017 127 43 54 10.1172/JCI88880 28045398 PMC5199705 [163.] Coelho M. Oliveira T. Fernandes R. Biochemistry of adipose tissue: An endocrine organ Arch. Med. Sci. 2013 9 191 200 10.5114/aoms.2013.33181 23671428 PMC3648822 [164.] Rosen E.D. Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis Nature 2006 444 847 853 10.1038/nature05483 17167472 PMC3212857 [165.] Gastaldelli A. Gaggini M. DeFronzo R.A. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study Diabetes 2017 66 815 822 10.2337/db16-1167 28052966 [166.] Czech M.P. Mechanisms of insulin resistance related to white, beige, and brown adipocytes Mol. Metab. 2020 34 27 42 10.1016/j.molmet.2019.12.014 32180558 PMC6997501 [167.] Scherer P.E. The many secret lives of adipocytes: Implications for diabetes Diabetologia 2019 62 223 232 10.1007/s00125-018-4777-x 30465066 PMC6324990 [168.] Maki K.C. Kelley K.M. Lawless A.L. Hubacher R.L. Schild A.L. Dicklin M.R. Rains T.M. Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test Diabetes Technol. Ther. 2011 13 661 666 10.1089/dia.2010.0240 21457067 [169.] Titchenell P.M. Lazar M.A. Birnbaum M.J. Unraveling the Regulation of Hepatic Metabolism by Insulin Trends Endocrinol. Metab. 2017 28 497 505 10.1016/j.tem.2017.03.003 28416361 PMC5477655 [170.] Cherrington A.D. Moore M.C. Sindelar D.K. Edgerton D.S. Insulin action on the liver in vivo Biochem. Soc. Trans. 2007 35 1171 1174 10.1042/BST0351171 17956305 [171.] Edgerton D.S. Lautz M. Scott M. Everett C.A. Stettler K.M. Neal D.W. Chu C.A. Cherrington A.D. Insulin’s direct effects on the liver dominate the control of hepatic glucose production J. Clin. Investig. 2006 116 521 527 10.1172/JCI27073 16453026 PMC1359060 [172.] Van Schaftingen E. Gerin I. The glucose-6-phosphatase system Biochem. J. 2002 362 513 532 10.1042/bj3620513 11879177 PMC1222414 [173.] Oh K.J. Han H.S. Kim M.J. Koo S.H. CREB and FoxO1: Two transcription factors for the regulation of hepatic gluconeogenesis BMB Rep. 2013 46 567 574 10.5483/BMBRep.2013.46.12.248 24238363 PMC4133859 [174.] Montal E.D. Dewi R. Bhalla K. Ou L. Hwang B.J. Ropell A.E. Gordon C. Liu W.J. DeBerardinis R.J. Sudderth J. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth Mol. Cell. 2015 60 571 583 10.1016/j.molcel.2015.09.025 26481663 PMC4656111 [175.] Leclercq I.A. Da Silva Morais A. Schroyen B. Van Hul N. Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences J. Hepatol. 2007 47 142 156 10.1016/j.jhep.2007.04.002 17512085 [176.] Meshkani R. Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease Clin. Biochem. 2009 42 1331 1346 10.1016/j.clinbiochem.2009.05.018 19501581 [177.] Gast K.B. Tjeerdema N. Stijnen T. Smit J.W. Dekkers O.M. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: Meta-analysis PLoS ONE 2012 7 e52036 10.1371/journal.pone.0052036 23300589 PMC3532497 [178.] Haffner S.M. Lehto S. Ronnemaa T. Pyorala K. Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 1998 339 229 234 10.1056/NEJM199807233390404 9673301 [179.] Beckman J.A. Creager M.A. Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management JAMA 2002 287 2570 2581 10.1001/jama.287.19.2570 12020339 [180.] Nesto R.W. Correlation between cardiovascular disease and diabetes mellitus: Current concepts Am. J. Med. 2004 116 Suppl. 5 11S 22S 10.1016/j.amjmed.2003.10.016 15019859 [181.] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002 106 3143 3421 10.1161/circ.106.25.3143 12485966 [182.] Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals Arterioscler. Thromb. Vasc. Biol. 2012 32 1754 1759 10.1161/ATVBAHA.111.241885 22815340 [183.] Bornfeldt K.E. Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis Cell. Metab. 2011 14 575 585 10.1016/j.cmet.2011.07.015 22055501 PMC3217209 [184.] Davidson J.A. Parkin C.G. Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes Diabetes Care 2009 32 Suppl. 2 S331 S333 10.2337/dc09-S333 19875575 PMC2811466 [185.] Laakso M. Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development Nat. Rev. Endocrinol. 2014 10 293 302 10.1038/nrendo.2014.29 24663222 [186.] Battisti W.P. Palmisano J. Keane W.E. Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease Clin. Chem. Lab. Med. 2003 41 1174 1181 10.1515/CCLM.2003.181 14598867 [187.] Lewis G.F. Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state Diabetes Care 1996 19 390 393 10.2337/diacare.19.4.390 8729170 [188.] Sparks J.D. Sparks C.E. Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol. 2012 32 2104 2112 10.1161/ATVBAHA.111.241463 22796579 [189.] Verges B. Pathophysiology of diabetic dyslipidaemia: Where are we? Diabetologia 2015 58 886 899 10.1007/s00125-015-3525-8 25725623 PMC4392164 [190.] Taskinen M.R. Diabetic dyslipidaemia: From basic research to clinical practice Diabetologia 2003 46 733 749 10.1007/s00125-003-1111-y 12774165 [191.] Chapman M.J. Ginsberg H.N. Amarenco P. Andreotti F. Boren J. Catapano A.L. Descamps O.S. Fisher E. Kovanen P.T. Kuivenhoven J.A. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management Eur. Heart J. 2011 32 1345 1361 10.1093/eurheartj/ehr112 21531743 PMC3105250 [192.] Nordestgaard B.G. Varbo A. Triglycerides and cardiovascular disease Lancet 2014 384 626 635 10.1016/S0140-6736(14)61177-6 25131982 [193.] Boren J. Matikainen N. Adiels M. Taskinen M.R. Postprandial hypertriglyceridemia as a coronary risk factor Clin. Chim. Acta 2014 431 131 142 10.1016/j.cca.2014.01.015 24508990 [194.] Dallinga-Thie G.M. Kroon J. Boren J. Chapman M.J. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr. Cardiol. Rep. 2016 18 67 10.1007/s11886-016-0745-6 27216847 PMC4877422 [195.] Varbo A. Freiberg J.J. Nordestgaard B.G. Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study Clin. Chem. 2018 64 219 230 10.1373/clinchem.2017.279463 29021326 [196.] Bernelot Moens S.J. Verweij S.L. Schnitzler J.G. Stiekema L.C.A. Bos M. Langsted A. Kuijk C. Bekkering S. Voermans C. Verberne H.J. Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans Arterioscler. Thromb. Vasc. Biol. 2017 37 969 975 10.1161/ATVBAHA.116.308834 28336558 [197.] Steinberg D. Carew T.E. Fielding C. Fogelman A.M. Mahley R.W. Sniderman A.D. Zilversmit D.B. Lipoproteins and the pathogenesis of atherosclerosis Circulation 1989 80 719 723 10.1161/01.CIR.80.3.719 2670321 [198.] Cohn J.S. Marcoux C. Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins Arterioscler. Thromb. Vasc. Biol. 1999 19 2474 2486 10.1161/01.ATV.19.10.2474 10521378 [199.] Grundy S.M. Cleeman J.I. Daniels S.R. Donato K.A. Eckel R.H. Franklin B.A. Gordon D.J. Krauss R.M. Savage P.J. Smith S.C. Jr. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement Curr. Opin. Cardiol. 2006 21 1 6 10.1097/01.hco.0000200416.65370.a0 16355022 [200.] Grundy S.M. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds J. Am. Coll. Cardiol. 2006 47 1093 1100 10.1016/j.jacc.2005.11.046 16545636 [201.] Ginsberg H.N. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis Diabetes Care 1991 14 839 855 10.2337/diacare.14.9.839 1959476 [202.] Adiels M. Boren J. Caslake M.J. Stewart P. Soro A. Westerbacka J. Wennberg B. Olofsson S.O. Packard C. Taskinen M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia Arterioscler. Thromb. Vasc. Biol. 2005 25 1697 1703 10.1161/01.ATV.0000172689.53992.25 15947244 [203.] Verges B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes Atherosclerosis 2010 211 353 360 10.1016/j.atherosclerosis.2010.01.028 20189175 [204.] Lin M.C. Gordon D. Wetterau J.R. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: Insulin negatively regulates MTP gene expression J. Lipid. Res. 1995 36 1073 1081 7658155 [205.] Blasiole D.A. Davis R.A. Attie A.D. The physiological and molecular regulation of lipoprotein assembly and secretion Mol. Biosyst. 2007 3 608 619 10.1039/b700706j 17700861 [206.] Fisher E.A. Ginsberg H.N. Complexity in the secretory pathway: The assembly and secretion of apolipoprotein B-containing lipoproteins J. Biol. Chem. 2002 277 17377 17380 10.1074/jbc.R100068200 12006608 [207.] Choi S.H. Ginsberg H.N. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance Trends Endocrinol. Metab. 2011 22 353 363 10.1016/j.tem.2011.04.007 21616678 PMC3163828 [208.] Horton J.D. Goldstein J.L. Brown M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver J. Clin. Investig. 2002 109 1125 1131 10.1172/JCI0215593 11994399 PMC150968 [209.] Kanter J.E. Shao B. Kramer F. Barnhart S. Shimizu-Albergine M. Vaisar T. Graham M.J. Crooke R.M. Manuel C.R. Haeusler R.A. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes J. Clin. Investig. 2019 129 4165 4179 10.1172/JCI127308 31295146 PMC6763229 [210.] Haas M.E. Attie A.D. Biddinger S.B. The regulation of ApoB metabolism by insulin Trends Endocrinol. Metab. 2013 24 391 397 10.1016/j.tem.2013.04.001 23721961 PMC3810413 [211.] Laatsch A. Merkel M. Talmud P.J. Grewal T. Beisiegel U. Heeren J. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance Atherosclerosis 2009 204 105 111 10.1016/j.atherosclerosis.2008.07.046 18834984 [212.] Gordts P.L. Nock R. Son N.H. Ramms B. Lew I. Gonzales J.C. Thacker B.E. Basu D. Lee R.G. Mullick A.E. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors J. Clin. Investig. 2016 126 2855 2866 10.1172/JCI86610 27400128 PMC4966320 [213.] Toth P.P. Barter P.J. Rosenson R.S. Boden W.E. Chapman M.J. Cuchel M. D’Agostino R.B. Sr. Davidson M.H. Davidson W.S. Heinecke J.W. High-density lipoproteins: A consensus statement from the National Lipid Association J. Clin. Lipidol. 2013 7 484 525 10.1016/j.jacl.2013.08.001 24079290 [214.] Lewis G.F. Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport Circ. Res. 2005 96 1221 1232 10.1161/01.RES.0000170946.56981.5c 15976321 [215.] Van Lenten B.J. Fogelman A.M. Jackson R.L. Shapiro S. Haberland M.E. Edwards P.A. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages J. Biol. Chem. 1985 260 8783 8788 2991220 [216.] Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes Diabetes Care 2004 27 1496 1504 10.2337/diacare.27.6.1496 15161808 [217.] Lamarche B. Uffelman K.D. Carpentier A. Cohn J.S. Steiner G. Barrett P.H. Lewis G.F. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men J. Clin. Investig. 1999 103 1191 1199 10.1172/JCI5286 10207171 PMC408274 [218.] Navab M. Reddy S.T. Van Lenten B.J. Fogelman A.M. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms Nat. Rev. Cardiol. 2011 8 222 232 10.1038/nrcardio.2010.222 21304474 [219.] Khera A.V. Cuchel M. de la Llera-Moya M. Rodrigues A. Burke M.F. Jafri K. French B.C. Phillips J.A. Mucksavage M.L. Wilensky R.L. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N. Engl. J. Med. 2011 364 127 135 10.1056/NEJMoa1001689 21226578 PMC3030449 [220.] Zhou H. Shiu S.W. Wong Y. Tan K.C. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in type 2 diabetes mellitus Diabetes Vasc. Dis. Res. 2009 6 238 243 10.1177/1479164109344934 20368217 [221.] Lathief S. Inzucchi S.E. Approach to diabetes management in patients with CVD Trends Cardiovasc. Med. 2016 26 165 179 10.1016/j.tcm.2015.05.005 26411567 [222.] Ference B.A. Ginsberg H.N. Graham I. Ray K.K. Packard C.J. Bruckert E. Hegele R.A. Krauss R.M. Raal F.J. Schunkert H. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur. Heart J. 2017 38 2459 2472 10.1093/eurheartj/ehx144 28444290 PMC5837225 [223.] McNamara J.R. Small D.M. Li Z. Schaefer E.J. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B J. Lipid. Res. 1996 37 1924 1935 8895058 [224.] Chait A. Brazg R.L. Tribble D.L. Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am. J. Med. 1993 94 350 356 10.1016/0002-9343(93)90144-E 8475928 [225.] Hoogeveen R.C. Gaubatz J.W. Sun W. Dodge R.C. Crosby J.R. Jiang J. Couper D. Virani S.S. Kathiresan S. Boerwinkle E. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk In Communities (ARIC) study Arterioscler. Thromb. Vasc. Biol. 2014 34 1069 1077 10.1161/ATVBAHA.114.303284 24558110 PMC3999643 [226.] Witztum J.L. Mahoney E.M. Branks M.J. Fisher M. Elam R. Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity Diabetes 1982 31 283 291 10.2337/diab.31.4.283 6818075 [227.] Bays H.E. Toth P.P. Kris-Etherton P.M. Abate N. Aronne L.J. Brown W.V. Gonzalez-Campoy J.M. Jones S.R. Kumar R. La Forge R. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association J. Clin. Lipidol. 2013 7 304 383 10.1016/j.jacl.2013.04.001 23890517 [228.] Mooradian A.D. Haas M.J. Wong N.C. Transcriptional control of apolipoprotein A-I gene expression in diabetes Diabetes 2004 53 513 520 10.2337/diabetes.53.3.513 14988232 [229.] Chung S. Sawyer J.K. Gebre A.K. Maeda N. Parks J.S. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo Circulation 2011 124 1663 1672 10.1161/CIRCULATIONAHA.111.025445 21931081 PMC3202242 [230.] McGillicuddy F.C. Reilly M.P. Rader D.J. Adipose modulation of high-density lipoprotein cholesterol: Implications for obesity, high-density lipoprotein metabolism, and cardiovascular disease Circulation 2011 124 1602 1605 10.1161/CIRCULATIONAHA.111.058453 21986773 PMC3928975 [231.] Zhang Y. McGillicuddy F.C. Hinkle C.C. O’Neill S. Glick J.M. Rothblat G.H. Reilly M.P. Adipocyte modulation of high-density lipoprotein cholesterol Circulation 2010 121 1347 1355 10.1161/CIRCULATIONAHA.109.897330 20212278 PMC2925122 [232.] Farbstein D. Levy A.P. HDL dysfunction in diabetes: Causes and possible treatments Expert Rev. Cardiovasc. Ther. 2012 10 353 361 10.1586/erc.11.182 22390807 PMC3332215 [233.] Eckel R.H. Grundy S.M. Zimmet P.Z. The metabolic syndrome Lancet 2005 365 1415 1428 10.1016/S0140-6736(05)66378-7 15836891 [234.] Ginsberg H.N. Insulin resistance and cardiovascular disease J. Clin. Investig. 2000 106 453 458 10.1172/JCI10762 10953019 PMC380256 [235.] Yusuf S. Hawken S. Ounpuu S. Dans T. Avezum A. Lanas F. McQueen M. Budaj A. Pais P. Varigos J. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study Lancet 2004 364 937 952 10.1016/S0140-6736(04)17018-9 15364185 [236.] Guyton J.R. Slee A.E. Anderson T. Fleg J.L. Goldberg R.B. Kashyap M.L. Marcovina S.M. Nash S.D. O’Brien K.D. Weintraub W.S. Relationship of lipoproteins to cardiovascular events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) J. Am. Coll. Cardiol. 2013 62 1580 1584 10.1016/j.jacc.2013.07.023 23916935 PMC3862446 [237.] Athyros V.G. Tziomalos K. Karagiannis A. Mikhailidis D.P. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment Open Cardiovasc. Med. J. 2011 5 24 34 10.2174/1874192401105010024 21660248 PMC3109607 [238.] Paneni F. Beckman J.A. Creager M.A. Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I Eur. Heart J. 2013 34 2436 2443 10.1093/eurheartj/eht149 23641007 PMC3743069 [239.] Cholesterol Treatment Trialists C. Kearney P.M. Blackwell L. Collins R. Keech A. Simes J. Peto R. Armitage J. Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis Lancet 2008 371 117 125 10.1016/S0140-6736(08)60104-X 18191683 [240.] Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications J. Clin. Endocrinol. Metab. 2009 94 3171 3182 10.1210/jc.2008-2534 19509100 [241.] Kessler L. Wiesel M.L. Attali P. Mossard J.M. Cazenave J.P. Pinget M. Von Willebrand factor in diabetic angiopathy Diabetes Metab. 1998 24 327 336 9805643 [242.] Giannini C. Mohn A. Chiarelli F. Kelnar C.J. Macrovascular angiopathy in children and adolescents with type 1 diabetes Diabetes Metab. Res. Rev. 2011 27 436 460 10.1002/dmrr.1195 21433262 [243.] Yamagishi S. Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy Oxid. Med. Cell. Longev. 2010 3 101 108 10.4161/oxim.3.2.11148 20716934 PMC2952094 [244.] Sena C.M. Pereira A.M. Seica R. Endothelial dysfunction—a major mediator of diabetic vascular disease Biochim. Biophys. Acta 2013 1832 2216 2231 10.1016/j.bbadis.2013.08.006 23994612 [245.] Margetic S. Inflammation and haemostasis Biochem. Med. (Zagreb.) 2012 22 49 62 10.11613/BM.2012.006 22384519 PMC4062321 [246.] Wautier J.L. Guillausseau P.J. Diabetes, advanced glycation endproducts and vascular disease Vasc. Med. 1998 3 131 137 10.1177/1358836X9800300207 9796076 [247.] Bakker W. Eringa E.C. Sipkema P. van Hinsbergh V.W. Endothelial dysfunction and diabetes: Roles of hyperglycemia, impaired insulin signaling and obesity Cell. Tissue Res. 2009 335 165 189 10.1007/s00441-008-0685-6 18941783 [248.] Libby P. Inflammation in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 2012 32 2045 2051 10.1161/ATVBAHA.108.179705 22895665 PMC3422754 [249.] Badimon L. Padro T. Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease Eur. Heart J. Acute Cardiovasc. Care 2012 1 60 74 10.1177/2048872612441582 24062891 PMC3760546 [250.] Hotamisligil G.S. Inflammation and metabolic disorders Nature 2006 444 860 867 10.1038/nature05485 17167474 [251.] Lecube A. Pachon G. Petriz J. Hernandez C. Simo R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement PLoS ONE 2011 6 e23366 10.1371/journal.pone.0023366 21876749 PMC3158070 [252.] Lee H.M. Kim J.J. Kim H.J. Shong M. Ku B.J. Jo E.K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes Diabetes 2013 62 194 204 10.2337/db12-0420 23086037 PMC3526026 [253.] Meng X.F. Wang X.L. Tian X.J. Yang Z.H. Chu G.P. Zhang J. Li M. Shi J. Zhang C. Nod-like receptor protein 1 inflammasome mediates neuron injury under high glucose Mol. Neurobiol. 2014 49 673 684 10.1007/s12035-013-8551-2 24014157 [254.] Koenen T.B. Stienstra R. van Tits L.J. de Graaf J. Stalenhoef A.F. Joosten L.A. Tack C.J. Netea M.G. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue Diabetes 2011 60 517 524 10.2337/db10-0266 21270263 PMC3028351 [255.] Zeadin M.G. Petlura C.I. Werstuck G.H. Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis Can. J. Diabetes 2013 37 345 350 10.1016/j.jcjd.2013.06.001 24500563 [256.] Menegazzo L. Ciciliot S. Poncina N. Mazzucato M. Persano M. Bonora B. Albiero M. Vigili de Kreutzenberg S. Avogaro A. Fadini G.P. NETosis is induced by high glucose and associated with type 2 diabetes Acta. Diabetol. 2015 52 497 503 10.1007/s00592-014-0676-x 25387570 [257.] Joshi M.B. Lad A. Bharath Prasad A.S. Balakrishnan A. Ramachandra L. Satyamoorthy K. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation FEBS Lett. 2013 587 2241 2246 10.1016/j.febslet.2013.05.053 23735697 [258.] Northcott J.M. Yeganeh A. Taylor C.G. Zahradka P. Wigle J.T. Adipokines and the cardiovascular system: Mechanisms mediating health and disease Can. J. Physiol. Pharmacol. 2012 90 1029 1059 10.1139/y2012-053 22646022 [259.] Yamawaki H. Vascular effects of novel adipocytokines: Focus on vascular contractility and inflammatory responses Biol. Pharm. Bull. 2011 34 307 310 10.1248/bpb.34.307 21372376 [260.] Maeda N. Shimomura I. Kishida K. Nishizawa H. Matsuda M. Nagaretani H. Furuyama N. Kondo H. Takahashi M. Arita Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat. Med. 2002 8 731 737 10.1038/nm724 12068289 [261.] Kim J.Y. van de Wall E. Laplante M. Azzara A. Trujillo M.E. Hofmann S.M. Schraw T. Durand J.L. Li H. Li G. Obesity-associated improvements in metabolic profile through expansion of adipose tissue J. Clin. Investig. 2007 117 2621 2637 10.1172/JCI31021 17717599 PMC1950456 [262.] Yamauchi T. Kamon J. Ito Y. Tsuchida A. Yokomizo T. Kita S. Sugiyama T. Miyagishi M. Hara K. Tsunoda M. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 2003 423 762 769 10.1038/nature01705 12802337 [263.] Fang H. Judd R.L. Adiponectin Regulation and Function Compr. Physiol. 2018 8 1031 1063 10.1002/cphy.c170046 29978896 [264.] Ye R. Wang M. Wang Q.A. Scherer P.E. Adiponectin-mediated antilipotoxic effects in regenerating pancreatic islets Endocrinology 2015 156 2019 2028 10.1210/en.2015-1066 25815422 PMC4430619 [265.] Mandal P. Pratt B.T. Barnes M. McMullen M.R. Nagy L.E. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: Link between the metabolic and innate immune activity of full-length adiponectin J. Biol. Chem. 2011 286 13460 13469 10.1074/jbc.M110.204644 21357416 PMC3075692 [266.] Caligiuri A. Bertolani C. Guerra C.T. Aleffi S. Galastri S. Trappoliere M. Vizzutti F. Gelmini S. Laffi G. Pinzani M. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells Hepatology 2008 47 668 676 10.1002/hep.21995 18098312 [267.] Ezenwaka C.E. Kalloo R. Caribbean female patients with type 2 diabetes mellitus have lower serum levels of adiponectin than nondiabetic subjects Neth. J. Med. 2005 63 64 69 15766010 [268.] Dullaart R.P. Kappelle P.J. Dallinga-Thie G.M. Carotid intima media thickness is associated with plasma adiponectin but not with the leptin:adiponectin ratio independently of metabolic syndrome Atherosclerosis 2010 211 393 396 10.1016/j.atherosclerosis.2010.03.024 20398901 [269.] Iwashima Y. Katsuya T. Ishikawa K. Ouchi N. Ohishi M. Sugimoto K. Fu Y. Motone M. Yamamoto K. Matsuo A. Hypoadiponectinemia is an independent risk factor for hypertension Hypertension 2004 43 1318 1323 10.1161/01.HYP.0000129281.03801.4b 15123570 [270.] Pilz S. Horejsi R. Moller R. Almer G. Scharnagl H. Stojakovic T. Dimitrova R. Weihrauch G. Borkenstein M. Maerz W. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin J. Clin. Endocrinol. Metab. 2005 90 4792 4796 10.1210/jc.2005-0167 15928248 [271.] Sattar N. Wannamethee G. Sarwar N. Tchernova J. Cherry L. Wallace A.M. Danesh J. Whincup P.H. Adiponectin and coronary heart disease: A prospective study and meta-analysis Circulation 2006 114 623 629 10.1161/CIRCULATIONAHA.106.618918 16894037 [272.] Ouchi N. Kihara S. Arita Y. Nishida M. Matsuyama A. Okamoto Y. Ishigami M. Kuriyama H. Kishida K. Nishizawa H. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages Circulation 2001 103 1057 1063 10.1161/01.CIR.103.8.1057 11222466 [273.] Yang R.Z. Lee M.J. Hu H. Pray J. Wu H.B. Hansen B.C. Shuldiner A.R. Fried S.K. McLenithan J.C. Gong D.W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action Am. J. Physiol. Endocrinol. Metab. 2006 290 E1253 E1261 10.1152/ajpendo.00572.2004 16531507 [274.] Landecho M.F. Tuero C. Valenti V. Bilbao I. de la Higuera M. Fruhbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk Nutrients 2019 11 2664 10.3390/nu11112664 31694146 PMC6893824 [275.] Schaffler A. Neumeier M. Herfarth H. Furst A. Scholmerich J. Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue Biochim. Biophys. Acta 2005 1732 96 102 10.1016/j.bbaexp.2005.11.005 16386808 [276.] Auguet T. Quintero Y. Riesco D. Morancho B. Terra X. Crescenti A. Broch M. Aguilar C. Olona M. Porras J.A. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women BMC Med. Genet. 2011 12 60 10.1186/1471-2350-12-60 21526992 PMC3107780 [277.] Pan H.Y. Guo L. Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes Diabetes Res. Clin. Pract. 2010 88 29 33 10.1016/j.diabres.2010.01.013 20129687 [278.] Tan B.K. Adya R. Farhatullah S. Lewandowski K.C. O’Hare P. Lehnert H. Randeva H.S. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose Diabetes 2008 57 801 808 10.2337/db07-0990 18174521 [279.] Cai R.C. Wei L. Di J.Z. Yu H.Y. Bao Y.Q. Jia W.P. Expression of omentin in adipose tissues in obese and type 2 diabetic patients Zhonghua Yi Xue Za Zhi 2009 89 381 384 19567114 [280.] Elsaid N.H. Sadik N.A. Ahmed N.R. Fayez S.E. Mohammed N.A.E. Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters J. Clin. Transl. Endocrinol. 2018 13 14 19 10.1016/j.jcte.2018.05.003 30023310 PMC6047309 [281.] Wang J. Gao Y. Lin F. Han K. Wang X. Omentin-1 attenuates lipopolysaccharide (LPS)-induced U937 macrophages activation by inhibiting the TLR4/MyD88/NF-kappaB signaling Arch. Biochem. Biophys. 2020 679 108187 10.1016/j.abb.2019.108187 31706880 [282.] Fernandez-Trasancos A. Agra R.M. Garcia-Acuna J.M. Fernandez A.L. Gonzalez-Juanatey J.R. Eiras S. Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells Obesity (Silver Spring) 2017 25 1042 1049 10.1002/oby.21832 28429889 [283.] Zabetian-Targhi F. Mirzaei K. Keshavarz S.A. Hossein-Nezhad A. Modulatory Role of Omentin-1 in Inflammation: Cytokines and Dietary Intake J. Am. Coll. Nutr. 2016 35 670 678 10.1080/07315724.2015.1126207 27331575 [284.] Dimova R. Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis Biomed. Res. Int. 2015 2015 823481 10.1155/2015/823481 25945347 PMC4402467 [285.] Esteghamati A. Noshad S. Mousavizadeh M. Zandieh A. Nakhjavani M. Association of vaspin with metabolic syndrome: The pivotal role of insulin resistance Diabetes Metab. J. 2014 38 143 149 10.4093/dmj.2014.38.2.143 24851208 PMC4021301 [286.] Choi S.H. Kwak S.H. Lee Y. Moon M.K. Lim S. Park Y.J. Jang H.C. Kim M.S. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women Clin. Endocrinol. (Oxf.) 2011 75 628 635 10.1111/j.1365-2265.2011.04095.x 21545478